Poster Presentations Session V
Poster Presentations Session V Wednesday, 8 November 2017
POSTERS SET-UP: 8:30 - 8:45
POSTERS DISPLAY HOURS: 8:45 - 14:00
POSTER AUTHOR DISCUSSION: 13:00 - 14:00
POSTERS DISMANTLE: 14:00


Poster display locations are shown below the poster codes
RESEARCH ON METHODS - Clinical Outcomes Methods
PRM1
A1
COMPARISON OF VARIOUS SEVERITY ASSESSMENT SCORING SYSTEMS IN PATIENTS WITH SEPSIS
Badrinath K1, Shekhar M1, Moturu SL1, Kunhikatta V1, Thunga G1, Nileshwar KR2
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Kasturba Medical College, Manipal, Manipal University, Manipal, India

PRM2
A2
COULD EMBASE EMTREE INDEX SEARCH TERMS BE FOCUSED TO REDUCE NUMBERS TO SCREEN IN CLINICAL SYSTEMATIC REVIEWS?
Cadwell K, Fox D, Jones G
PHMR Ltd, London, UK

PRM3
A3
A REAL WORLD EVIDENCE (RWE) APPROACH TO CHARACTERISING AN ULTRA-RARE DISEASE (URD) COHORT OF METASTATIC UVEAL MELANOMA (MUM) PATIENTS WITHIN NATIONAL HEALTH SERVICE ENGLAND (NHSE)
Schwenkglenks M1, Alamgir G2, Cheng C3, Adams EJ3, Toward T4
1European Center of Pharmaceutical Medicine - University of Basel, Basel, Switzerland, 2Health iQ Ltd, London, UK, 3Aquarius Population Health Limited, London, UK, 4Immunocore Limited, Abingdon, UK

PRM4
A4
EVALUATING ENDPOINTS AND CHANGING TRENDS IN ADVANCED STAGES OF CANCER RELATED CLINICAL TRIALS
Kim H1, Lee J1, Song SY2, Kim E3
1Department of Pharmaceutical Industry Management, The Graduate School, Chung-Ang University, Seoul, Korea, Republic of (South), 2Chung-Ang University College of Pharmacy, Seoul, Korea, Republic of (South), 3Evidence-Based Research and Clinical Research Lab., Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South)

PRM5
A5
COGNITIVE ASSESSMENTS ON PORTABLE DEVICES: A COMPARISON BETWEEN PHONES AND TABLETS
Jansen J1, van de Loo A1, Garssen J2, Scholey A3, Tiplady B4, Verster J1
1Utrecht University, Utrecht, The Netherlands, 2Nutricia Research, Utrecht, The Netherlands, 3Swinburne University, Melbourne, Australia, 4University of Edinburgh, Edinburgh, UK

PRM6
A6
USING CONVERGENT MIXED METHODS TO EVALUATE TREATMENT RISKS AND BENEFITS IN RARE DISEASE: AN EXAMPLE FROM A PHASE II REGISTRATION TRIAL IN METASTATIC MERKEL CELL CARCINOMA
Bharmal M1, Guillemin I2, Marrel A2, Lambert J2, Arnould B2, Fatoumata F2, Hennessy M3, Dias-Barbosa C2
1Merck KGaA, Darmstadt, Germany, 2Mapi, Patient-Centered Outcomes, Lyon, France, 3EMD Serono, Billerica, MA, USA

PRM7
A7
VALIDATION OF SURROGATE ENDPOINTS IN MELANOMA THERAPIES AND USE IN HTA
Hopkinson D1, Chadwick C1, Bibi M1, Bastian A2
1McCann Health, Macclesfield, UK, 2Incyte Corporation, Wilmington, DE, USA

PRM8
A8
ANALYSIS OF EFFECTIVENESS CRITERIA IN PHARMACOECONOMIC STUDIES OF ANTIMICROBIAL THERAPEUTIC AGENTS PROPOSED FOR INCLUSION IN THE ESSENTIAL DRUG LIST (RUSSIA) IN 2014-2016.
Kolbin A, Gomon Y
Pavlov Medical University, St.Petersburg, Russian Federation

PRM9
A9
REVIEW OF SURROGATE ENDPOINT VALIDATION METHODOLOGIES AND APPLICATION IN SOLID TUMOUR HTAS
Hopkinson D1, Chadwick C1, Bibi M1, Bastian A2
1McCann Health, Macclesfield, UK, 2Incyte Corporation, Wilmington, DE, USA

PRM10
A10
IMPACT OF DRUG RELATED PROBLEMS ON BLOOD PRESSURE CONTROL IN PATIENTS WITH HYPERTENSION IN INDONESIAN PRIMARY HEALTH CARE
Rahmawati F, Andayani TM, Wijayanti L, Lefiani L
Universitas Gadjah Mada, Yogyakarta, Indonesia

PRM11
A11
CLINICAL EVALUATION OF CEA , CA125, CA19-9 and CA72-4 IN GASTRIC CANCER PATIENTS WITH ADJUVANT CHEMOTHERAPY
Abbas M1, Fransis S1, Naveed M1, Mohammad IS1, Tengli C1, Nepal A1, Thao DT1, Meiqi S2, Dingding C1
1China Pharmaceutical University, School of Pharmacy, Nanjing, China, 2Jiangsu Cancer Hospital, Nanjing, China

PRM12
A12
NOVEL BIOLOGICS VERSUS CONVENTIONAL PREVENTIVE THERAPIES IN MIGRAINE: A FRAMEWORK FOR ECONOMIC EVALUATION
Lipton RB1, Brennan A2, Palmer S3, Jansen JP4, Hatswell AJ5, Porter JK6, Di Tanna GL6, Villa G6, Shah N7, Sapra S7
1Albert Einstein College of Medicine, Bronx, NY, USA, 2University of Sheffield, Sheffield, UK, 3University of York, Heslington, York, UK, 4Precision Health Economics, Los Angeles, CA, USA, 5BresMed Health Solutions, Sheffield, UK, 6Amgen (Europe) GmbH, Zug, Switzerland, 7Amgen Inc, Thousand Oaks, CA, USA

PRM13
A13
STATISTICAL METHODS FOR CRITICAL CARE OUTCOMES
Exuzides A1, Filonenko A2, Kunz M2, Gerlinger C2, Chu BC1, Bhurke S1, Sites S1
1Evidera, Bethesda, MD, USA, 2Bayer AG, Berlin, Germany

PRM14
A14
METHODOLOGICAL ISSUES WITH KEY DRUG VALUE FRAMEWORKS
Kloc K1, Lach S1, Chouaid C2, Borget I3, Rémuzat C4, Toumi M5
1Creativ-Ceutical, Krakow, Poland, 2Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 3Gustave Roussy, Villejuif, France, 4Creativ-Ceutical, Paris, France, 5Aix-Marseille University, Marseille, France

PRM15
A15
CURRENT AND POTENTIAL FUTURE CHANGES IN THE METHODOLOGY OF EMERGING VALUE FRAMEWORKS
Kloc K1, Lach S1, Chouaid C2, Borget I3, Rémuzat C4, Toumi M5
1Creativ-Ceutical, Krakow, Poland, 2Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 3Gustave Roussy, Villejuif, France, 4Creativ-Ceutical, Paris, France, 5Aix-Marseille University, Marseille, France

PRM16
A16
LONG TERM EFFICACY OF PERTUZUMAB FOR HER2+ METASTASIC BREAST CANCER ECUADORIAN POPULATION
Briceno V1, Lupera H2
1Massachusetts College of Pharmacy & Health Sciences, Boston, MA, Ecuador, 2Hospital Metropolitano, Quito, Ecuador

PRM17
A17
CREATING INDIVIDUALIZED HBA1C TARGETS USING PREDICTIVE MODELING
Karpati T1, Curtis BH2, Feldman B1, Strizek AA2, Leventer-Roberts M1, He X3, Raz I4, Levin Iaina N3, Rubin G5, Balicer RD6
1Clalit Health Services, Tel Aviv, Israel, 2Eli Lilly and Company, Sydney, Australia, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Hadassah Medical Organization, Jerusalem, Israel, 5Eli Lilly and Company, Israel, Ra’anana, Israel, 6Clalit Research Institute, Tel Aviv, Israel

PRM18
A18
MAXIMIZING THE VALUE OF WEARABLE BY THE REMOTE COLLECTION AND ANALYSIS OF RAW 100HZ DATA
Smith L1, McCarthy M2, Phillips M1, Muehlhausen W2, Byrom B3
1ICON plc, Dublin 18, Ireland, 2ICON Clinical Research, Dublin, Ireland, 3ICON Clinical Research, Marlow, UK

PRM19
A19
PARAMETRIC MODELLING OF MIGRAINE DAY FREQUENCY IN MIGRAINE PREVENTION: A CASE STUDY OF ERENUMAB CLINICAL TRIAL DATA
Porter JK1, Di Tanna GL1, Villa G1, Brennan A2, Palmer S3, Lipton RB4, Jansen JP5, Shah N6, Desai P6, Sapra S6
1Amgen (Europe) GmbH, Zug, Switzerland, 2University of Sheffield, Sheffield, UK, 3University of York, Heslington, York, UK, 4Albert Einstein College of Medicine, Bronx, NY, USA, 5Precision Health Economics, Los Angeles, CA, USA, 6Amgen Inc, Thousand Oaks, CA, USA

PRM20
A20
TREATMENT SWITCHING AND POWER OF ITT AND RPSFTM
Ouwens MJ1, Dalevi D1, Igl W2
1Astrazeneca, Molndal, Sweden, 2Astrazeneca, Cambridge, Sweden

PRM21
A21
AN ALGORITHM TO QUANTTTATIVELY ESTIMATE EXTRAPOLATED LIFETIME SURVIVAL CURVES FOR ECONOMIC EVALUATION (EE) OF CANCER TREATMENTS WHEN ONLY AGGREGATED PATIENT DATA ARE AVAILABLE; WITH APPLICATION TO METASTATIC PANCREATIC CANCER
Gharaibeh M, Alsaid N, Abraham I
Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona (Tucson, AZ, USA), Tucson, AZ, USA

PRM22
A22
INCLUSION OF COMPARATOR SINGLE ARM TRIALS USED FOR EMA/FDA REGISTRATION IN THE NETWORK META-ANALYSIS USING MATCHING ADJUSTED INDIRECT COMPARISONS
Ouwens MJ
Astrazeneca, Molndal, Sweden

PRM23
A23
COMPARATIVE EFFECTIVENESS OF VENETOCLAX IN VIEW OF A CLINICAL TRIAL WITH NO CONTROL GROUP
Deticek A, Mardetko N, Kos M, Locatelli I
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PRM24
A24
A VALIDATION STUDY OF THE RANK-PRESERVING STRUCTURAL FAILURE TIME MODEL: CONFIDENCE INTERVALS, UNIQUE, MULTIPLE AND ERRONEOUS SOLUTIONS
Ouwens MJ1, Hauch O2, Franzen S3
1Astrazeneca, Molndal, Sweden, 2Hauch consultancy, Saint-Gillis, Belgium, 3Registercentrum västra götaland, Göteborg, Sweden

PRM25
A25
SUBGROUP SPECIFIC MEDICINE: FINDING PATIENTS WITH POOR THERAPY RESPONSE
Simon A, Hapfelmeier J
Arvato Health Analytics GmbH, Munich, Germany

PRM26
A26
AN ANALYSIS OF TRANSLATION CHALLENGES WHEN ADAPTING THE PICTURE NAMING SUBTEST OF THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS) FOR USE IN MULTINATIONAL STUDIES
Bartolic E1, Nakonechny A2, Popielnicki A3, Sweeney E4, Weatherholtz R5
1CogState, New Haven, CT, USA, 2TransPerfect, London, UK, 3TransPerfect, Boston, MA, USA, 4TransPerfect, New York, NY, USA, 5TransPerfect, San Francisco, CA, USA

PRM27
A27
IQWIG´S GENERAL METHODS 5.0 - WHAT´S NEW?
Krieger T
RTI Health Solutions, Quickborn, Germany

PRM28
B1
USING AN INSTRUMENTAL VARIABLE APPROACH TO ESTIMATE CAUSAL TREATMENT EFFECTS IN AN OBSERVATIONAL COHORT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
John E, Abrams KR, Sheehan N, Brightling C
University of Leicester, Leicester, UK

PRM29
B2
USING ELECTRONIC HEALTH RECORDS AS A REAL WORLD COMPARATOR: A CASE STUDY IN A SINGLE ARM ONCOLOGY TRIAL
Davies J1, Martinec M2, Crane G3, Coudert M4, Rosenthal R2, Knoerzer D5, Martina R6
1Roche Products Ltd, Welwyn Garden City, UK, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3Roche (RWD), Welwyn Garden City, UK, 4Roche S.A.S., Boulogne-Billancourt cedex, France, 5Roche Pharma AG, Grenzach-Wyhlen, Germany, 6University of Liverpool, Liverpool, UK

PRM30
B3
CONCEPTUALIZATION, DEVELOPMENT, AND INTERNAL AND EXTERNAL VALIDATION OF A ‘WHOLE DISEASE’ MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Ghanbarian S, Sin D, Adibi A, FitzGerald JM, Bryan S, Sadatsafavi M
University of British Columbia, Vancouver, BC, Canada

RESEARCH ON METHODS - Cost Methods
PRM31
B4
COMPARING COSTS AND OUTCOMES BETWEEN COBLATION TECHNOLOGY AND MECHANICAL DEBRIDEMENT IN THE TREATMENT OF KNEE CARTILAGE LESIONS- A COST-EFFECTIVENESS ANALYSIS FROM A US PAYER PERSPECTIVE
Adeyemi A1, Nherera L2, Trueman P2, Delhougne G3
1Smith & Nephew, Andover, MA, USA, 2Smith & Nephew, Hull, UK, 3Smith & Nephew, Fort Worth, TX, USA

PRM32
B5
MEDICAL TRANSPORTATION COSTS IN FRANCE: WHICH SOURCE TO ESTIMATE THEM IN HEALTH-ECONOMIC ANALYSIS?
Messaoudi S, Sivignon M, Roze S
HEVA HEOR Sarl, Lyon, France

PRM33
B6
BROADENING THE VALUATION SPACE IN HEALTH TECHNOLOGY ASSESSMENT: THE CASE OF MONITORING INDIVIDUALS WITH OCULAR HYPERTENSION
Hernández R1, Vale L2, Ryan M1, Burr J3
1Health Economics Research Unit, University of Aberdeen, Aberdeen, UK, 2Newcastle University, Newcastle upon Tyne, UK, 3University of St andrews, St Andrews, Fife, UK

PRM34
B7
COST –EFFECTIVENESS OF OBINUTUZUMAB AS FRONTLINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN REPUBLIC OF MACEDONIA
Kapedanovska Nestorovska A, Sterjev Z, Naumovska Z, Grozdanova A, Dimovski A, Suturkova L
ISPOR Republic of Macedonia regional chapter, Skopje, Macedonia

PRM35
B8
ASSESSMENT OF HEALTHCARE COSTS OF INFANTS IN EXCLUSIVE BREASTFEEDING VERSUS MIXED OR ARTIFICIAL BREASTFEED.
Hidalgo A1, Santacruz-Salas E2, Aranda-Reneo I2
1University of Castilla-La Mancha, Toledo, Spain, 2University of Castilla-La Mancha, Talavera de la Reina, Spain

PRM36
B9
PHARMACOECONOMIC EVALUATION OF SORAFENIB AS FIRST-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA
Naumovska Z1, Kapedanovska Nestorovska A1, Grozdanova A2, Suturkova L3, Dimovski A2, Sterjev Z3
1Faculty of Pharmacy, Skopje, Macedonia, The former Yugoslav Republic of, 2ISPOR Republic of Macedonia regional chapter, Skopje, Macedonia, 3Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia

PRM37
B10
WORK ACCIDENT COSTS . SECURITY, HEALTHCARE AND HUMAN RESOURCES DEPARTMENTS LINKS .
Tanaka GK1, Alves TF2, Coan MF2, Lozovey JC3, Tanaka F2, Tanaka E4
1PEQUENO PRINCIPE SCHOOL OF MEDICINE, CURITIBA , PARANÁ , BRAZIL, Brazil, 2FEDERAL UNIVERSITY OF PARANÁ, CURITIBA , PARANÁ , BRAZIL, Brazil, 3UNIVERSIDADE FEDERAL DO PARANÁ, CURITIBA , PARANÁ, Brazil, 4ICS, CURITIBA , PARANÁ , BRAZIL, Brazil

PRM38
B11
ASSESSMENT OF QUALITY OF HEALTH ECONOMIC STUDIES IN NON-ALCOHOLIC FATTY LIVER DISEASE
Khan RA1, Adil M1, Ghosh P2
1School of Pharmaceutical Education and Research, Jamia Hamdard (Hamdard University), New Delhi, India, 2Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, India

PRM39
B12
THE DESIGN OF ECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF BIOSIMILARS: A QUALITATIVE STUDY
Moorkens E1, Broux H1, Huys I1, Vulto A2, Declerck P1, Simoens S1
1KU Leuven, Leuven, Belgium, 2The Erasmus University Medical Center, Rotterdam, The Netherlands

PRM40
B13
EXPLAINING WAITING TIMES FOR SCHEDULED SURGERY USING A HIGH-DIMENSIONAL FIXED EFFECTS MODEL
Cima J, Guimarães P, Almeida AS
Faculdade de Economia, Universidade do Porto, Porto, Portugal

PRM41
B14
HEALTH INSURANCE PERSPECTIVE AND COLLECTIVE PERSPECTIVE: THE DIFFERENCES IN THE COLLECTION AND VALUATION OF COST DATA IN FRANCE
Carette J, Roze S, Petitjean A, Gherardi A
HEVA HEOR Sarl, Lyon, France

PRM42
B15
A UNIFORM PROBABILISTIC APPROACH TO MANAGE UNCERTAINTIES REGARDING VACCINE EFFECTIVENESS AGAINST SEROTYPE 3, 19A, NTHI AND HERD EFFECT IN THE BASE CASE OF A COST-EFFECTIVENESS ANALYSIS COMPARING NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D (PHID-CV) WITH 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINES (PCV13) IN INFANTS
Olbrecht J1, Simone B2, Izurieta P1
1GSK, Wavre, Belgium, 2GSK, Uxbridge, Middlesex, UK

PRM43
B16
HORIZON SCANNING IN ONCOLOGY – RAPID SCANNING APPROACH IN SLOVAKIA
Tomek D1, Mrva P2, Marusakova E3
1Slovak Medical University, Bratislava, Slovak Republic, 2Ministry of Health of the Slovak Republic, Bratislava, Slovakia, 3Slovak Society of Pharmacoeconomics, Bratislava, Slovakia

PRM44
B17
THE IMPORTANCE OF PERSPECTIVE WHEN EVALUATING THE ECONOMIC VALUE OF VOCATIONAL REHABILITATION
McManus E1, Sach TH1, Radford K2, On behalf of the FRESH Trial Team .2
1University of East Anglia, Norwich, UK, 2University of Nottingham, Nottingham, UK

PRM45
B18
IDENTIFYING COST EFFECTIVE METHODS OF HEALTH TECHNOLOGY ASSESSMENT FOR DEVELOPERS – THE NEED FOR FAST AND FRUGAL EVALUATION
Bouttell J1, Hawkins N2, Briggs A2
1The University of Glasgow, Glasgow, UK, 2University of Glasgow, Glasgow, UK

PRM46
B19
WHICH INFORMATION SOURCES SHOULD BE USED TO IDENTIFY STUDIES FOR SYSTEMATIC REVIEWS OF ECONOMIC EVALUATIONS IN HEALTHCARE?
Arber M, Wood H, Isojarvi J, Glanville J
York Health Economics Consortium, York, UK

PRM47
B20
SINGLE DISTRIBUTION, TWO-PART, AND TWO-COMPONENT FINITE MIXTURE MODELS FOR PREDICTING SMOKING-RELATED INDIRECT COSTS IN US WORKING ADULTS
Li VW1, Goren A2, Baker CL3, Bruno MC3, Emir B3
1Kantar Health, New York, NJ, USA, 2Kantar Health, New York, NY, USA, 3Pfizer Inc., New York, NY, USA

PRM48
B21
ACCOUNTING FOR CAPACITY CONSTRAINTS IN ECONOMIC EVALUATIONS OF STRATIFIED MEDICINE: A SYSTEMATIC REVIEW
Wright SJ, Moore H, Daker-White G, Newman W, Payne K
The University of Manchester, Manchester, UK

PRM49
B22
REPORTED LIMITATIONS IN ECONOMIC MODELS FOR TREATMENTS OF SCHIZOPHRENIA: A SYSTEMATIC LITERATURE REVIEW
Zhou J1, Millier A2, Dorey J2, Aballéa S2, Toumi M1
1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France

PRM50
B23
COST-EFFECTIVENESS ANALYSIS OF CHIDAMIDE VERSUS CHEMOTHERAPY ON THE TREATMENT OF PERIPHERAL T - CELL LYMPHOMA PATIENTS IN CHINA
Ma J1, Shi Y2, Zhu J3, Jiang W4, Li J5, Shen Z6, Cao G7, Zhang J7, Yang F8, Xuan J9
1Harbin Institute of Hematology and Oncology, Harbin, China, 2Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Lymphoma division,Beijing Cancer Hospital, Beijing, China, 4Cancer prevention and treatment center of Zhongshan University, guangzhou, China, 5Jiangsu Province Hospital, nanjing, China, 6Ruijin Hospital,Shanghai Jiaotong University School of Medicine, shanghai, China, 7Shenzhen Chipscreen Bioscience Ltd, shenzhen, China, 8Shanghai Centennial Scientific Ltd, Shanghai, China, 9Institute of Pharmaceutical Economics, Sun Yat - sen University, guangzhou, China

PRM51
B24
PREDICTING BUDGET IMPACT: A MIXED-EFFECTS MODEL APPROACH
Geenen JW, Belitser SV, Vreman RA, Klungel O, Raaijmakers JA, Hovels A
Utrecht University, Utrecht, The Netherlands

PRM52
B25
SYSTEMATIC REVIEW OF COHORT-LEVEL ECONOMIC MODELS FOR ANTIPSYCHOTICS IN SCHIZOPHRENIA
Zhou J1, Millier A2, Dorey J2, Aballéa S2, Toumi M1
1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France

PRM53
B26
THE IMPACT OF THE LEARNING CURVE ON COSTS AND EFFECTS OF NOVEL MEDICAL DEVICES. EVIDENCE FROM REGISTRY DATA
Federici C, Armeni P, Costa F, Tarricone R
SDA Bocconi School of Management, Milan, Italy

PRM54
B27
MONTECARLO MODEL AS A TOOL IN ESTIMATION OF ECONOMIC BURDEN OF A DISEASE THROUGH THE PREDICTION OF BIOLOGICAL CHARACTERISTICS OF TUMOR IN BREAST CANCER
Balderas-Peña L1, Sat-Muñoz D2, Martinez-Herrera B3, Avalos-Nuño J4, Gonzalez-Barba F1, Cruz-Corona E1, Ortiz-González F5
1UMAE Hospital de Especialidades Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, 2Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico, 3Hospital General de Zona No. 2 "Dr. Francisco Padrón Puyou", San Luis Potosí, SLP, Mexico, 4UMAE Hospital de Gineco-Obstetricia Centro Médico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico, 5Unidad Médica de Alta Especialidad Hospital de Especialidades. Centro Médico Nacional de Occidente, Guadalajara, Jalisco, Mexico

PRM55
C1
MODELING TECHNIQUES FOR FITTING HEALTHCARE RESOURCE USE COSTS DERIVED FROM PATIENT REPORTED COUNTS OF HOSPITAL, ER, AND PCP VISITS
Liebert R, Sanders A, Kudel I
Kantar Health, New York, NY, USA

PRM56
C2
WHAT IS THE SCOPE AND QUALITY OF ECONOMIC EVIDENCE AVAILABLE FOR ATOPIC ECZEMA? A SYSTEMATIC REVIEW
Sach TH1, McManus E1, Levell N2, McOwan F3, Parris J3, Roberts A3, Thomas K3
1University of East Anglia, Norwich, UK, 2Norfolk and Norwich University Hospital, Norwich, UK, 3University of Nottingham, Nottingham, UK

PRM57
C3
CLASSIFICATION OF CAUSES OF HOSPITALIZATION FOR HEART FAILURE PATIENTS IN COST-EFFECTIVENESS AND COST-UTILITY EVALUATIONS OF PHARMACOTHERAPEUTIC, SURGICAL, AND MANAGED-CARE INTERVENTIONS: SYSTEMATIC REVIEW
Alsaid N1, Sweitzer N2, Ramos K3, Erstad B4, Slack M4, Abraham I1
1Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona (Tucson, AZ, USA), Tucson, AZ, USA, 2Sarver Heart Center, University of Arizona (Tucson, AZ, USA), Tucson, AZ, USA, 3College of Medicine, University of Arizona (Phoenix, AZ. USA), Phoenix, AZ, USA, 4Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona (Tucson, AZ, USA), Tucson, AZ, USA

PRM58
C4
THE DYNAMICS OF CHILD MENTAL HEALTH CARE
Dijk HH, Freriks RD, Mierau JO
University of Groningen, Groningen, The Netherlands

RESEARCH ON METHODS - Databases & Management Methods
PRM59
C5
CONVERSION OF A FRENCH ELECTRONIC MEDICAL RECORD (EMR) DATABASE INTO THE OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP COMMON DATA MODEL.
Schwalm M1, Raoul T1, Chu D2, Shah U3, Potdar M4, Van Zandt M5, Coffin G1, Jouaville SL1
1QuintilesIMS, La Defense, France, 2QuintilesIMS, Philadelphia, PA, USA, 3QuintilesIMS, Parsippany, NJ, USA, 4QuintilesIMS, Warren, NJ, USA, 5QuintilesIMS, San Francisco, CA, USA

PRM60
C6
IS IT POSSIBLE TO ACCURATELY IDENTIFY RARE DISEASES USING NATIONAL HOSPITAL DISCHARGE DATABASES?
Bergot E1, de Léotoing L2, Bendjenana H3, Tournier C2, Vainchtock A2, Nachbaur G3, Humbert M4
1CHU Côté de Nacre, Caen, France, 2HEVA, LYON, France, 3GSK, Marly-le-Roi, France, 4Hôpital de Bicêtre, Le Kremlin Bicêtre, France

PRM61
C7
REGULATORY & REIMBURSEMENT DECISIONS DATABASE FOR INNOVATIVE DRUGS TO IMPROVE CONSISTENCY OF DECISION-MAKING
Augustynska J, Skora K, Walczak J, Tomassy J
Arcana Institute Ltd, Krakow, Poland

PRM62
C8
COMPARISON OF ICD-9 TO ICD-10 CROSSWALKS DERIVED BY PHYSICIAN AND CLINICAL CODER VS. AUTOMATED METHODS
Simeone J1, Bhagnani TD1, Rhodes T2, Reynolds M1
1Evidera, Waltham, MA, USA, 2Merck, North Wales, PA, USA

PRM63
C9
INSIGHT INTO THE ROLE OF THE GENERAL PRACTITIONER IN THE MANAGEMENT OF COLORECTAL CANCER: RECORD LINKAGE OF THE NETHERLANDS CANCER REGISTRY AND THE GENERAL PRACTITIONER DATABASE OF THE PHARMO DATABASE NETWORK
Kuiper JG1, van Herk-Sukel MP2, Lemmens VE3, van Wijngaarden R4, Herings RM5
1Erasmus University Medical Center, Rotterdam, The Netherlands, 2University Medical Center Utrecht, Utrecht, The Netherlands, 3Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 4STIZON, Utrecht, The Netherlands, 5PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PRM64
C10
LEVERAGING ELECTRONIC HEALTH RECORDS TO MEET THE REAL WORLD EVIDENCE NEEDS OF HTA: A UK PERSPECTIVE
Sammon C, Glover M
PHMR Ltd, London, UK

PRM65
C11
A REVIEW OF CLINICAL OUTCOME ASSESSMENT LABELING IN EUROPE AND IN THE UNITED STATES (2013-2016)
Arnould B1, Pierson RF2, Chan E2, Savre I3, Acquadro C4
1Mapi, Patient-Centered Outcomes, Lyon, France, 2Janssen Global Services, LLC, Raritan, NJ, USA, 3Mapi Research Trust, Lyon, France, 4Mapi, Lyon, France

PRM66
C12
IDENTIFICATION OF REAL WORLD DATA SOURCES IN CANCER IN THE NORDIC COUNTRIES
Vertuani S1, Hernlund E2, Klint J2, Miikkulainen K2, Paulsson B1, Jacob J1
1Novartis Oncology Nordics, Stockholm, Sweden, 2Mapi Group, Stockholm, Sweden

PRM67
C13
INCREASING CLINICAL DATA QUALITY THROUGH INTERACTIVE DATA VISUALIZATION
Vlamynck G, Pau D, Magrez D, veleno-Salotti A
Roche, Boulogne-Billancourt, France

PRM68
C14
A SNAPSHOT OF MEDICATION ADHERENCE ACROSS THREE EUROPEAN COUNTRIES: APPLICATION OF COMMON METHODOLOGY
Menditto E1, Cahir C2, Aza M3, Poblador Plou B4, Malo S5, Bruzzese D1, González Rubio F4, Kardas P6, Prados-Torres A3
1University of Naples Federico II, Naples, Italy, 2Royal College of Surgeons in Ireland, Dublin, Ireland, 3Aragon Health Service (SALUD), Zaragoza, Spain, 4Aragon Health Sciences Institute (IACS). IIS Aragón, REDISSEC ISCIII, Zaragoza, Spain, 5University of Zaragoza, Zaragoza, Spain, 6Department of Family Medicine, Medical University of Lodz, Lodz, Poland

PRM69
C15
I-O OPTIMISE: DEVELOPING A UNIQUE MULTINATIONAL REAL-WORLD EVIDENCE-BASED RESEARCH PLATFORM IN ONCOLOGY
Durand-Zaleski I1, Manley-Daumont M2, Baas P3, Chaib C4, Chao D5, Chouaid C6, Ekman S7, d’Estrube T8, Griesinger F9, Juarez-Garcia A10, Khovratovich M8, Layton D8, McNamara A11, O’Donnell JC12, Penrod JR13, Pereira M14, Toft Sørensen H15
1URC Eco, Paris, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3The Netherlands Cancer Institute, Amsterdam, The Netherlands, 4Bristol-Myers Squibb, Madrid, Spain, 5The Royal Free Hospital, London, UK, 6Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France, 7Karolinska University Hospital, Stockholm, Sweden, 8QuintilesIMS, London, UK, 9Pius-Hospital Oldenburg, Oldenburg, Germany, 10Bristol-Myers Squibb, Mexico City, Mexico, 11Irish Cancer Society, Dublin, Ireland, 12Bristol-Myers Squibb Co., Princeton, NJ, USA, 13Bristol-Myers Squibb, Princeton, NJ, USA, 14Bristol-Myers Squibb, Uxbridge, UK, 15Aarhus University Hospital, Aarhus, Denmark

PRM70
C16
MISCLASSIFICATION OF DIABETES TYPE I IN GERMAN CLAIMS DATA
Schmid K, Hapfelmeier J
Arvato Health Analytics GmbH, Munich, Germany

PRM71
C17
USING OBSERVATIONAL DATA FROM REGISTRY IN COST-EFFECTIVENESS EVALUATION OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER IN FRANCE
Leleu H1, Wapenaar R2, Klumper E3, Capone C4, de Beaucoudrey L4, Thevenon J4, Chevalier J4
1Public Health Expertise, Paris, France, 2Janssen-Cilag B.V., Breda, The Netherlands, 3SMS-Oncology BV, Amsterdam, The Netherlands, 4Janssen-Cilag, Issy-les-Moulineaux, France

PRM72
C18
THE PERSONALISED REIMBURSEMENT MODELS (PRM): REAL WORLD DATA COLLECTION TO PROVIDE INNOVATIVE PRICING SOLUTIONS IN FRANCE
Doly A1, Coudert B2, Cottu P3, Manson J4, Barletta H5, Perol D6, Aujoulat O7, Azria D8, Pivot X9, Montastier R10, Grandfils N11, Pinguet J12, Machuron V10, Samelson L10, Tehard B12
1CLINIDOM, Clermont-Ferrand, France, 2Centre Georges François Leclerc, Dijon, France, 3Institut Curie, Paris, France, 4Centre hospitalier René Dubos, Cergy Pontoise, France, 5Ramsay Générale de Santé, Hôpital Privé Drome Ardèche, Valence, France, 6Centre Léon Bérard, Lyon, France, 7GHR Mulhouse et Sud Alsace, Mulhouse, France, 8Institut du Cancer de Montpellier, Montpellier, France, 9CHRU Jean Minjoz, Besançon, France, 10Roche France, Boulogne Billancourt, France, 11, Levallois, France, 12Roche, Boulogne-Billancourt, France

PRM73
C19
IDENTIFYING PATIENTS WITH LUPUS NEPHRITIS IN THE UNITED KINGDOM (UK) CLINICAL PRACTICE RESEARCH DATALINK (CPRD)
McDonald L1, Ramagopalan S1, Burns L2, Postema R1
1Bristol-Myers Squibb, Uxbridge, UK, 2Bristol-Myers Squibb, Lawrence Township, NJ, USA

PRM74
C20
ROCHE ONCOLOGY DATA IN OPEN ACCESS: AN INNOVATIVE STEP FOR SCIENTISTS
Vlamynck G1, Pau D1, Petzold L1, Magrez D1, Petit-Nivard J2
1Roche, Boulogne-Billancourt, France, 2Roche, Boulogne Billancourt, France

PRM75
C21
ASSESSING THE VALUE OF DECISION TREES AS A METHOD FOR IDENTIFYING PATIENT SUBGROUPS
Risson V1, Jayanti H2, Filho E3, Rigg J2, Skelly A1, Bezlyak V1, Regnier SA1
1Novartis Pharma AG, Basel, Switzerland, 2QuintilesIMS, London, UK, 3SAS Switzerland, Zurich, Switzerland

PRM76
C22
ADJUSTING FOR SELECTION BIAS IN EVALUATING TWO-DOSE HUMAN PAPILLOMAVIRUS VACCINE COVERAGE AMONG ADOLESCENTS IN THE UNITED STATES
Kurosky S, Trantham L
RTI Health Solutions, Research Triangle Park, NC, USA

PRM77
C23
ANALYSIS OF USING IRP AS A LAUNCH PRICE SETTING MECHANISM
Ladron de Guevara P, Patel P
Global Pricing Innovations, London, UK

PRM78
C24
COMPARISON OF VARIOUS META-ANALYSIS TECHNIQUES
Wang L1, Lewis-Beck C2, Fritschel E3, Baser E1, Shrestha S1, Baser O4
1STATinMED Research, Plano, TX, USA, 2Iowa State University, Ames, IA, USA, 3UCLA Health, Los Angeles, CA, USA, 4Columbia University and STATinMED Research, New York, NY, USA

PRM79
C25
GUIDANCE FOR DEVELOPING A STUDY PROTOCOL OF A CAUSAL COMPARATIVE EFFECTIVENESS ANALYSIS IN “BIG DATA”: THE CASE OF WHEN TO START STATIN TREATMENT
Kuehne F1, Jahn B1, Conrads-Frank A1, Urach C2, Popper N3, Siebert U4
1Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 2DEXHELPP, Vienna, Austria, 3dwh GmbH, simulation services / Technical University, Institute for Analysis and Scientific Computing, Vienna, Austria, 4UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health. Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA

PRM80
C26
REAL WORLD EVIDENCE IN GLAUCOMATOUS DISEASES: EMR DATA IS INDISPENSIBLE FOR UNDERSTANDING PATIENT JOURNEYS AND OPTIMIZING CARE
Spera C1, Kim Y1, Bezlyak V1, Sagkriotis A1, Durus A1, Milnes F1, Gondos A2, Boxall NS3, Wintermantel T4, Ahmed F5
1Novartis Pharma AG, Basel, Switzerland, 2QuintilesIMS, Frankfurt, Germany, 3QuintilesIMS, London, UK, 4QuintilesIMS, Basel, Switzerland, 5Imperial College Ophthalmic Research Group, Western Eye Hospital, London, UK

PRM81
C27
OVERCOMING THE LIMITATIONS OF CLAIMS DATA: LINKAGE OF CLAIMS DATA WITH SECONDARY DATA SOURCES IN GERMANY
Jacob C, Guenther J, Borchert K, Krinke K, Braun S
Xcenda GmbH, Hannover, Germany

PRM82
D1
ETHICAL CONSIDERATIONS: CONDUCTING RETROSPECTIVE NON-INTERVENTIONAL MEDICAL RECORD REVIEW STUDIES IN EUROPE
Levine CA1, Ansquer V2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2AplusA Research, LYON, France

RESEARCH ON METHODS - Modeling Methods
PRM83
D2
A SYSTEMATIC REVIEW OF CALIBRATION IN POPULATION MODELS
Conrads-Frank A1, Jahn B2, Bundo M3, Sroczynski G1, Mühlberger N1, Bicher M4, Rippinger C5, Gyimesi M6, Endel G7, Popper N8, Siebert U9
1UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 2Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, 3UMIT - University for Health Sciences, Medical Informatics and Technology / Institute of Public Health, Medical Decision Making and Health Technology Assessment, Hall i.T., Austria, 4Technical University, Institute for Analysis and Scientific Computing, Vienna, Austria, 5DEXHELPP, Vienna, Austria, 6Austrian Public Health Institute, Vienna, Austria, 7Main Association of Austrian Social Insurance Institutions, Vienna, Austria, 8dwh GmbH, simulation services / Technical University, Institute for Analysis and Scientific Computing, Vienna, Austria, 9UMIT, Dept. of Public Health, Health Services Research & HTA / Harvard Univ., Dept. Health Policy & Management, Institute for Technology Assessment, Boston, MA / Hall i. T., Austria

PRM84
D3
HOW CAN MIDDLE-INCOME COUNTRIES GET A VALID ESTIMATE OF COST-EFFECTIVENESS OF A DRUG MORE EFFICIENTLY AND EFFECTIVELY?
Ansaripour A1, Severens JL1, Uyl-de Groot CA1, Redekop WK2
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

PRM85
D4
FINDING UNDIAGNOSED PATIENTS WITH HEPATITIS C VIRUS: AN APPLICATION OF STATE-OF-THE-ART MACHINE LEARNING METHODS
Doyle OM, Jayanti H, Homola D, Rigg J
QuintilesIMS, London, UK

PRM86
D5
THE IMPACT OF HUMAN PAPILLOMAVIRUS VACCINE IN TAIWAN: A TRANSMISSION DYNAMIC MODELLING APPROACH
Wen Y1, Chang S1, Chou T1, Wu H1, Lin YJ1, Fann SJ2, Chou H3, Chang CJ1
1Chang Gung University, Taoyuan, Taiwan, 2Academia Sinica, Taipei, Taiwan, 3Chang Gung Memorial Hospital, Taoyuan, Taiwan

PRM87
D6
BAYESIAN METHODOLOGY CONSIDERING HISTORICAL DATA TO PREDICT OVERALL SURVIVAL FROM IMMATURE TRIAL DATA IN ONCOLOGY
Soikkeli F1, Hashim M2, Postma M3, Heeg B2
1University of Eastern Finland, Kuopio, Finland, 2Ingress Health, Rotterdam, The Netherlands, 3University of Groningen, Groningen, The Netherlands

PRM88
D7
PROBABILISTIC SENSITIVITY ANALYSIS IN HEALTH ECONOMIC MODELS; HOW MANY SIMULATIONS SHOULD WE RUN?
Hatswell AJ1, Bullement A1, Paulden M2, Stevenson M3
1BresMed Health Solutions, Sheffield, UK, 2University of Alberta, Edmonton, AB, Canada, 3University of Sheffield, Sheffield, UK

PRM89
D8
APPROACHES TO MODELLING THE COST-EFFECTIVENESS OF INTERVENTIONS FOR HEART FAILURE: A SYSTEMATIC REVIEW
Sadler S1, Watson L1, Crathorne L1, Green C2
1University of Exeter, Exeter, UK, 2Exeter University, Exeter, UK

PRM90
D9
TRANSPARENCY MATTERS: USE OF DIGITAL SOFTWARE PLATFORM IN REPLICATING SYSTEMATIC REVIEWS
Husain F, Sayre T, Feinman T, Fazeli MS, Kuang Y, del Aguila MA
Doctor Evidence, Santa Monica, CA, USA

PRM91
D10
DETERMINANTS OF THE RELATIONSHIP BETWEEN IMPROVED GLUCOSE CONTROL AND MODELED HEALTH OUTCOMES IN TYPE 2 DIABETES SIMULATION MODELS
Foos V1, Lamotte M1, Altrabsheh E2, Sathananthan A2, McEwan P3
1QuintilesIMS, Zaventem, Belgium, 2QuintilesIMS, London, UK, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM92
D11
CLINICAL DRIVERS OF ECONOMIC MODELS AND UTILITY MAPPING ALGORITHMS IN SCHIZOPHRENIA
Nemeth B1, Fasseeh AN1, Molnar A1, Horvath M2, Koczian K2, Gotze A2, Nagy B3
1Syreon Research Institute, Budapest, Hungary, 2Gedeon Richter Plc., Budapest, Hungary, 3Eötvös Loránd University (ELTE), Budapest, Hungary

PRM93
D12
MODELLING CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES IN THE ERA OF CARDIOVASCULAR OUTCOMES TRIALS
McEwan P1, Chubb B2, Bennett H1
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Novo Nordisk Region Europe Pharmaceuticals A/S, Gatwick, UK

PRM94
D13
THE POTENTIAL VALUE OF REAL-WORLD EVIDENCE ALONG WITH TRIAL EFFICACY TO ESTIMATE EFFECTIVENESS OF NOVEL TREATMENTS IN REAL-WORLD SETTING; AN APPLICATION WITH OVERALL SURVIVAL IN TWO ONCOLOGY INDICATIONS
Soikkeli F1, Mueller S2, Groth A2, Hashim M1, Wilke T3, Heeg B1
1Ingress Health, Rotterdam, The Netherlands, 2Ingress-Health HWM GmbH, Wismar, Germany, 3INGRESS-Health HWM GmbH, Wismar, Germany

PRM95
D14
THE RELATIONSHIP OF PREDICTED BENEFITS IN LIFE EXPECTANCY AND QUALITY ADJUSTED LIFE EXPECTANCY FOR IMPROVED GLUCOSE CONTROL IN TYPE 2 DIABETES SIMULATION MODELING
Ramos M1, McEwan P2, Lamotte M1, Foos V1
1QuintilesIMS, Zaventem, Belgium, 2Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM96
D15
SURVIVAL OUTCOMES PREDICTED BY A DISCRETE EVENT SIMULATION MODEL FOR RENAL CELL CARCINOMA FOR USE IN A COST EFFECTIVENESS ANALYSIS: A COMPARISON WITH A TRADITIONAL PARTITIONED SURVIVAL MODEL
Treharne C1, Dansk V2, Santi I1, Malcolm B3, Johal S1
1Parexel International, London, UK, 2PAREXEL, Stockholm, Sweden, 3Bristol-Myers Squibb, Uxbridge, UK

PRM97
D16
NEW MODELLING APPROACHES IN OPHTHALMOLOGY: PARTITIONED VISION DISTRBUTION MODEL IN SYMPTOMATIC VITREOMACULAR ADHESION (VMA)/VITREOMACULAR TRACTION (VMT) WITH OR WITHOUT FULL-THICKNESS MACULAR HOLE (FTMH)
Bennison C1, Schmidt R2, Dugel PU3, Haller J4, Khanani AM5, Wagner A6, Lescrauwaet B7
1Pharmerit International, York, UK, 2Pharmerit International, Berlin, Germany, 3Retina Consultants of Arizona; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, 4Wills Eye Hospital, Philadelphia, PA, USA, 5Sierra Eye Associates, Reno, NV, USA, 6Wagner Macula and Retina Center, Eastern Virginia Medical School, Virginia Beach, VA, USA, 7Xintera Ltd, Cambridge, UK

PRM98
D17
DECISION ANALYTIC MODELLING METHODS FOR THE ASSESSING THE EFFECTIVENESS OF TREATMENT SEQUENCES FOR CLINICAL AND ECONOMIC DECISION MAKING: A METHODOLOGICAL REVIEW
Lewis RA, Hughes DA, Wilkinson C
Bangor University, Bangor, UK

PRM99
D18
IMPLEMENTATION OF A DATA MINING MODEL WITHIN A MONITORING WEB-BASED TOOL TO ASSESS HER2 BREAST CANCER STATUS USING THE HER-FRANCE REAL WORLD DATABASE
Vauléon T1, Pau D2, Dupin J3, Magrez D2, Martin J2, Bellocq J4
1Lincoln for Roche, Boulogne-Billancourt, France, 2Roche, Boulogne-Billancourt, France, 3ITM stat for Roche, Neuilly-sur-Seine, France, 4AFAQAP and Hospital of Strasbourg, Strasbourg, France

PRM100
D19
A DISCRETE EVENT SIMULATION MODEL FOR RENAL CELL CARCINOMA FOR USE IN A COST-EFFECTIVENESS ANALYSIS
Dansk V1, Treharne C2, Santi I2, Malcolm B3, Johal S2
1PAREXEL, Stockholm, Sweden, 2Parexel International, London, UK, 3Bristol-Myers Squibb, Uxbridge, UK

PRM101
D20
EXPLORATION OF RUN-TIME REQUIREMENTS IN PROBABILISTIC SENSITIVITY ANALYSIS UTILIZING A PATIENT LEVEL BASED TYPE 2 DIABETES SIMULATION MODEL
Foos V1, Lamotte M1, Sathananthan A2, Altrabsheh E2, McEwan P3
1QuintilesIMS, Zaventem, Belgium, 2QuintilesIMS, London, UK, 3Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM102
D21
THE EVALUATION OF ASSUMPTIONS IN COST-EFFECTIVENESS MODEL DEVELOPMENT – A CASE OF DABIGATRAN
Janzic A, Locatelli I
University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PRM103
D22
REPRESENTING UNCERTAINTY IN ECONOMIC EVALUATIONS: GETTING MORE FROM PSA RESULTS
Oguz M, Lanitis T
Evidera, London, UK

PRM104
D23
WITHDRAWN

PRM105
D24
A MARKOV MICROSIMULATION MODEL FOR THE ECONOMIC EVALUATION OF PARTIALLY IMPLANTABLE ACTIVE MIDDLE EAR IMPLANTS IN SENSORINEURAL HEARING LOSS
Kluibenschaedl M, Kosaner Kliess M, Urban M
MED-EL Medical Electronics, Innsbruck, Austria

PRM106
D25
REVIEW OF MODELS SUBMITTED TO NICE MEDICAL TECHNOLOGIES EVALUATION PROGRAMME TO INFORM A COST CONSEQUENCE TEMPLATE FOR USE IN MEDICAL TECHNOLOGIES GUIDANCE SUBMISSIONS
Eaton Turner E1, Craig J1, Jenks M1, Green W1, Shore J1, Hewitt N2, Dillon B2
1York Health Economics Consortium, York, UK, 2National Institute for Health and Care Excellence, Manchester, UK

PRM107
D26
COMPARISON OF STANDARD PARAMETRIC SURVIVAL METHODS VERSUS MORE FLEXIBLE APPROACHES
van Oostrum I1, Postma MJ2, Buskens E3, Heeg BM4
1University Medical Center Groningen (UMCG), Groningen, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3University Medical Center Groningen, Groningen, The Netherlands, 4Ingress-health Netherlands, Rotterdam, The Netherlands

PRM108
D27
METHODOLOGICAL ANALYSES OF BUDGET IMPACT MODELS SUBMITTED TO THE HAUTE AUTORITÉ DE SANTÉ (HAS) (FRENCH NATIONAL AUTHORITY FOR HEALTH)
Monnier R, Cartier-Bechu C, Gherardi A, Roze S
HEVA HEOR Sarl, Lyon, France

PRM109
E1
WITHDRAWN

PRM110
E2
MODELLING PATIENT PATHWAYS OF LOW-DOSE COMPUTED TOMOGRAPHY SCREENING FOR LUNG CANCER IN HUNGARY
Molnár A1, Nagy B1, Kerpel-Fronius A2, Bajzik G3, Horváth I2, Moizs M4, Vokó Z5
1Eötvös Loránd University (ELTE), Budapest, Hungary, 2National Korányi Institute for Pulmonology, Budapest, Hungary, 3Kaposvár University Health Center, Kaposvár, Hungary, 4Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary, 5Syreon Research Institute, Budapest, Hungary

PRM111
E3
A SYSTEMATIC REVIEW OF PREDICTIVE MODELS IN ACUTE HEART FAILURE
Viriato D1, Calado F2, Nallagangula TK3, Natani H3, Agrawal R3, Corda S2, Obergfell A2, Jindal R3
1Novartis Farma – Produtos Farmacêuticos S.A., Porto Salvo, Portugal, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Healthcare Pvt. Ltd., Hyderabad, India

PRM112
E4
EXPLORING STRUCTURAL UNCERTAINTY WITH AN OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR RHEUMATOID ARTHRITIS
Incerti D1, Curtis JR2, Lorenzi M1, Jansen JP3
1Innovation and Value Initiative, Los Angeles, CA, USA, 2University of Alabama at Birmingham, Birmingham, AL, USA, 3Precision Xtract, Oakland, CA, USA

PRM113
E5
UNCERTAINTY IN SELECTING SURVIVAL MODELS FOR COST EFFECTIVENESS ANALYSES
Pouwels XG, Joore MA, Ramaekers BL
Maastricht University Medical Center+, Maastricht, The Netherlands

PRM114
E6
COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS OF DRUGS FOR THE TREATMENT OF MULTIPLE MYELOMA
Carey N, Fogarty E, Bryan E, Tilson L
National Centre for Pharmacoeconomics, Dublin, Ireland

PRM115
E7
ECONOMIC EVALUATION OF A BRIEF COUNSELLING FOR SMOKING CESSATION IN DENTISTRY – A CASE STUDY COMPARING TWO HEALTH ECONOMIC MODELS
Feldman I1, Virtanen S2, Galanti MR2, Johansson P3
1Uppsala University, Uppsala, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Public Health & Economics, Huddinge, Sweden

PRM116
E8
COST-EFFECTIVENESS ANALYSIS OF INTERVENTIONS THAT HAVE NOT SHOWN CLINICAL EFFECTIVENESS
Teljeur C1, Harrington P2, O'Neill M2, Moran P3, Ryan M3
1Health Information and Quality Authority, Dublin, Ireland, 2Health Information and Quality Authority, Dublin 7, Ireland, 3Health Information and Quality Authority (HIQA), Dublin, Ireland

PRM117
E9
USING MATHEMATICAL OPTIMISATION IN MODEL-BASED COST-EFFECTIVENESS ANALYSES: A CASE STUDY OF A STRATIFIED BREAST SCREENING PROGRAMME
Donten A1, Gray E2, Payne K1
1The University of Manchester, Manchester, UK, 2University of Edinburgh, Edinburgh, UK

PRM118
E10
MODEL TYPES SUBMITTED TO NICE: WHAT IS CONSIDERED APPROPRIATE BY EVIDENCE REVIEW GROUPS?
Hearmon NC1, Ghosh W1, Buguth B1, Kusel J2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Consulting Ltd., London, UK

PRM119
E11
ISSUES ENCOUNTERED WHEN MODELLING THE LONG TERM CLINICAL EFFECTIVENESS OF TREATMENTS FROM SHORT TERM TRIALS USING SECOND-LINE TREATMENTS FOR ADVANCED OR METASTATIC RENAL CELL CARCINOMA (AMRCC) AS AN EXAMPLE
Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, Masento N, Salih F
BMJ, London, UK

PRM120
E12
EVALUATING THE IMPORTANCE OF REALISTICALLY SIMULATING RISK FACTOR PROGRESSION OVER TIME: A HEALTH ECONOMIC MODELING ANALYSIS IN TYPE 1 DIABETES
Pollock RF1, Hunt B2, Valentine WJ2
1Ossian Health Economics and Communications, Basel, Switzerland, 2Ossian Health Economics and Communications GmbH, Basel, Switzerland

PRM121
E13
HOW TO ADDRESS FRENCH HEALTH AUTHORITY (HAS/CEESP) SPECIFIC REQUIREMENTS IN MODELLING RELAPSING-REMITTING MULTIPLE SCLEROSIS IN HEALTH-ECONOMIC EVALUATION? MODELLING TREATMENT SEQUENCES
Cartier-Bechu C1, Sivignon M1, Petitjean A1, Roze S1, Pinguet J2, Tehard B2
1HEVA HEOR Sarl, Lyon, France, 2Roche, Boulogne-Billancourt, France

PRM122
E14
A COMPARISON OF MARKOV COHORT AND DISCRETE EVENT SIMULATION MODELS IN COST-EFFECTIVENESS ANALYSIS OF SORAFENIB AND EVEROLIMUS IN 3RD LINE METASTATIC RENAL-CELL CARCINOMA IN THE CZECH REPUBLIC
Mlcoch T, Lamblova K, Ornstova E, Dolezal T
Value Outcomes, Prague, Czech Republic

PRM123
E15
ASSESSING THE JOINT PROBABILITY OF COST-EFFECTIVENESS AND AFFORDABILITY IN DECISION MAKING
Yi Y, Lucherini S, Bellanca L, Heron L
Adelphi Values Ltd, Bollington, UK

PRM124
WITHDRAWN

PRM125
E16
WEB APP ESTIMATING COST SAVINGS AND CLINICAL OUTCOMES OF BLOOD GLUCOSE MONITORING PROGRAM. EXAMPLE FROM THE UK
Topachevskyi O1, Volovyk A2, Siabro V2
1Digital Health Outcomes, Brussels, Belgium, 2Digital Health Outcomes, Kiev, Ukraine

PRM126
E17
COST-EFFECTIVENESS OF A MULTI-GENE PANEL IN THE CONTEXT OF REDUCING ADVERSE DRUG REACTIONS
Plumpton CO1, Pirmohamed M2, Hughes DA1
1Bangor University, Bangor, UK, 2National Institute for Health Research, Collaborations for Leadership in Applied Health Research and Care, North West Coast (NIHR CLAHRC NWC), University of Liverpool, Liverpool, UK

PRM127
E18
INCORPORATING DEPENDENCE BETWEEN MODEL PARAMETERS IN UNCERTAINTY ANALYSES
Oguz M, Roiz J
Evidera, London, UK

PRM128
E19
COST-EFFECTIVENESS ANALYSIS OF 10% INTRAVENOUS IMMUNOGLOBULIN COMPARED WITH PLASMA EXCHANGE IN TREATMENT OF CHILDREN WITH GUILLAIN–BARRÉ SYNDROME IN RUSSIA
Ugrekhelidze D, Yagudina R, Kulikov A
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PRM129
E20
RISK ADJUSTMENTS IN ECONOMIC MODELS - WHAT IS THEIR IMPACT ON PREDICTED RATES?
Maruszczak M1, Villa G2, Lothgren M1
1Amgen, Economic Modeling COE, Zug, Switzerland, 2Amgen, Zug, Switzerland

PRM130
E21
VACCINE EFFICACY, EFFECTIVENESS, OR IMPACT: WHICH ONE TO CHOOSE IN ECONOMIC EVALUATIONS OF VACCINES?
Standaert B1, Dort T2, Toumi M3
1GSK, Wavre, Belgium, 2Keyrus Management S.A. on behalf of GSK, Strombeek-Bever, Belgium, 3Aix Marseille University Department of Public Health, Marseille, France

PRM131
E22
QUANTITY AND QUALITY OF EXTERNAL EVENT VALIDATION PROCEDURES PERFORMED IN PUBLISHED HEALTH ECONOMIC MODELS IN OBESITY: OUTCOMES OF A SYSTEMATIC REVIEW
Schwander B1, Nuijten M2, Hiligsmann M3, Evers S3
1AHEAD GmbH, Loerrach, Germany, 2A2M, Amsterdam, The Netherlands, 3Maastricht University, Maastricht, The Netherlands

PRM132
E23
SELECTING SOFTWARE PACKAGES FOR CONDUCTING COST-EFFECTIVENESS MODELLING IN HEALTH CARE
Stephens TJ, Selya-Hammer C, Gauthier A
Amaris, London, UK

PRM133
E24
CALIBRATING MODEL-CONSISTENT TRANSITION PROBABILITIES FOR FIBROSIS STAGES IN NASH
Gal P1, Roiz J2, Xiao Y2
1Evidera Inc., Budapest, Hungary, 2Evidera Inc., London, UK

PRM134
E25
COST-EFFECTIVENESS ANALYSIS OF VENETOCLAX FOR TREATMENT OF REFRACTORY/RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA WITH OR WITHOUT 17P DELETION IN BULGARIA
Djambazov S, Veleva N, Tsanova D, Vekov T
Medical University Pleven, Pleven, Bulgaria

PRM135
E26
DEVELOPING A CONCEPTUAL MODELLING FRAMEWORK FOR ECONOMIC EVALUATION
McMeekin N, Briggs A, Wu O
University of Glasgow, Glasgow, UK

PRM136
E27
ECONOMIC EVALUATION OF ANAFERON® IN THE TREATMENT OF ACUTE RESPIRATORY INFECTIONS IN MEXICO
Paladio-Hernández JÁ1, Pérez VM2
1UAM-Azcapotalco, Cuautitlán Izcalli, Mexico, 2BIOPHARMEX, Mexico City, Mexico

PRM137
F1
HIERARCHICAL BAYESIAN MODEL ACCOUNTS FOR HETEROGENEITY IN ONCOLOGISTS’ STATED PREFERENCE ON VARIOUS BREAST CANCER TREATMENTS
Shi A1, Talledo H2
1SAS, Cary, NC, USA, 2Universidad San Ignacio de Loyola and University of the Pacific in Lima, Lima, Peru

PRM138
F2
MAPPING FROM THE WOMAC TO THE EQ-5D-5L QUESTIONNAIRE: COMPARISON OF DIFFERENT METHODOLOGIES
Bilbao A1, Martín-Fernández J2, García-Perez L3, Arenaza JC4, García I5, Polentinos-Castro E6, Magdalena-Armas L7, Ansola L8
1Research Unit, Basurto University Hospital (Osakidetza) – Health Service Research Network on Chronic Diseases (REDISSEC), Bilbao, Spain, 2Villamanta Centre, Navalcarnero Health Centre, Madrid Health Service – REDISSEC, Madrid, Spain, 3Fundación Canaria de Investigación Sanitaria (FUNCANIS) – REDISSEC, Tenerife, Spain, 4Traumatology and Orthopedic Surgery Service, Basurto University Hospital (Osakidetza) – REDISSEC, Bilbao, Spain, 5Traumatology and Orthopedic Surgery Service, Galdakao-Usansolo Hospital (Osakidetza), Galdakao, Spain, 6Family and Community Care Teaching, North Unit, Madrid Health Service – REDISSEC, Madrid, Spain, 7Rheumatology Service, Nuestra Señora de Candelaria University Hospital, Tenerife, Spain, 8Research Unit, Basurto University Hospital (Osakidetza), Bilbao, Spain

PRM139
F3
A MODIFIED TIME TRADE-OFF EXPERIMENT IN EQ-5D-3L VALUATION WITH FUZZY HEALTH STATES UTILITIES
Jakubczyk M1, Golicki D2
1SGH Warsaw School of Economics, Warsaw, Poland, 2Department of Experimental & Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

PRM140
F4
MAPPING FROM THE BDI-II TO THE EQ-5D-5L QUESTIONNAIRE IN PATIENTS WITH MAJOR DEPRESSION DISORDER
Bilbao A1, García-Perez L2, Martín-Fernández J3, Retolaza-Balsategui A4, Arrasate M5, Sordo T6, Acosta-Artiles FJ7, Candela-Ramírez R8, Ansola L9
1Research Unit, Basurto University Hospital (Osakidetza) – Health Service Research Network on Chronic Diseases (REDISSEC), Bilbao, Spain, 2Fundación Canaria de Investigación Sanitaria (FUNCANIS) – REDISSEC, Tenerife, Spain, 3Villamanta Centre, Navalcarnero Health Centre, Madrid Health Service – REDISSEC, Madrid, Spain, 4Basauri Mental Health Center (Osakidetza) – REDISSEC, Basauri, Spain, 5Uribe Kosta Mental Health Center (Osakidetza), Getxo, Spain, 6Psychiatry Service, Basurto University Hospital (Osakidetza), Bilbao, Spain, 7Servicio de Salud Mental, Dirección General de Programas Asistenciales, Servicio Canario de la Salud, Tenerife, Spain, 8Fuenlabrada Mental Health Center, Fuenlabrada University Hospital, Madrid, Spain, 9Research Unit, Basurto University Hospital (Osakidetza), Bilbao, Spain

PRM141
F5
USING REGRESSION MODELS TO ACCOMMODATE HETEROGENEITY AND ADDRESS COHORT IMBALANCE IN PARAMETRIC SURVIVAL MODELS FOR USE IN HTA
Bojke C
University of Leeds, Leeds, UK

PRM142
F6
USING A "LANDMARK" APPROACH TO ARTIFICIALLY POPULATE THE COMPARATOR ARM OF AN ECONOMIC MODEL USING DATA FROM A PHASE II, UNCONTROLLED TRIAL IN ADVANCED BASAL CELL CARCINOMA
Loughran T1, Reyes A2, Pletscher M2, Krivasi T2
1Hoffmann-La Roche Ltd., Welwyn Garden City, UK, 2Hoffmann-La Roche Ltd, Basel, Switzerland

PRM143
F7
TACKLING NETWORK META-ANALYSIS METHODOLOGICAL CHALLENGES: A CASE STUDY ON BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN CHILDREN AND YOUNG PEOPLE
Saramago P, Duarte A, Palmer S, Rothery C
University of York, Heslington, York, UK

PRM144
F8
A MODEL FOR ALZHEIMER’S DISEASE IN THE PREVENTION SETTING
Caputo A1, Racine A1, Paule I1, Feller C1, Savelieva M1, Hummel N2, Karcher H2, Lopez Lopez C1, Graf A1
1Novartis Pharma AG, Basel, Switzerland, 2Analytica Laser, Loerrach, Germany

PRM145
F9
METHOD OF EXTRAPOLATION: ESTIMATION OF THE IMPACT OF THE PROPORTIONAL HAZARD ASSUMPTION ON THE EFFICACY ESTIMATION
Duteil E1, Kandel M2, Gori J3, Roze S4, Borget I5
1Novartis Pharma, Rueil-Malmaison, France, 2Institut Gustave Roussy, Villejuif, France, 3Telecom ParisTech, Université Paris-Saclay, Paris, France, 4HEVA HEOR Sarl, Lyon, France, 5Gustave Roussy, Villejuif, France

PRM146
F10
FROM EVALUATION TO OPTIMIZATION: USING A META-MODEL TO MAXIMIZE THE BENEFITS OF COLORECTAL SCREENING ACCOUNTING FOR CAPACITY CONSTRAINTS
Koffijberg H1, Coupe VM2, IJzerman MJ1, Greuter MJ2
1University of Twente, Enschede, The Netherlands, 2VU University Medical Center, Amsterdam, The Netherlands

PRM147
F11
SINGLE ARMED OBSERVATIONAL DATA TO CLOSING THE GAP IN OTHERWISE DISCONNECTED EVIDENCE NETWORKS
Schmitz S1, Maguire A2, Morris J3, Walsh C4
1Luxembourg Institute of Health, Strassen, Luxembourg, 2Trinity College Dublin, Dublin, Ireland, 3Cogentia Healthcare Consulting, Cambridge, UK, 4University of Limerick, Castletroy, Ireland

PRM148
F12
COST-EFFECTIVENESS OF MOLECULAR VERSUS CONVENTIONAL SCREENING FOR ACUTE INTESTINAL INFECTIOUS DISEASES: NOVEL APPLICATION OF AGENT-BASED MODELLING.
Bhatt R, Hughes DA
Bangor University, Bangor, UK

PRM149
F13
AN ALGORITHM TO DEVELOP CORRELATED MULTIVARIATE NON-NORMAL (E.G. BETA, GAMMA, LOG-NORMAL) DISTRIBUTIONS TO BE USED IN PROBABILISTIC SENSITIVITY ANALYSES (PSAS)
Neine M1, Curran D2
1Freelance C/O GSK, Wavre, Belgium, 2GSK, Wavre, Belgium

PRM150
F14
FRACTIONAL POLYNOMIAL MODELLING IN NETWORK META-ANALYSES OF CANCER IMMUNOTHERAPIES IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Chu P1, Watkins CL2
1F. Hoffman-La Roche Ltd, Basel, Switzerland, 2Clarostat Consulting Limited, Alderley Edge, UK

PRM151
F15
A PREDICTIVE TOOL FOR CHARACTERIZING AND VISUALIZING POPULATIONS UNDER COUNTERFACTUAL TREATMENT ASSIGNMENT
Chorev M1, Amit M1, Bak P2, Yaeli A2, El-Hay T1, Goldschmidt Y1
1IBM Research - Haifa, Haifa, Israel, 2IBM Watson Health, Haifa, Israel

PRM152
F16
HOW TO SAMPLE ORDERED PARAMETERS IN PROBABILISTIC SENSITIVITY ANALYSIS
Ren S1, Minton J2, Whyte S1, Latimer N1, Stevenson M1
1University of Sheffield, Sheffield, UK, 2University of Glasgow, Glasgow, UK

PRM153
F17
USING NETWORK META-ANALYSIS OF INDIVIDUAL PATIENT DATA (IPD) & SUMMARY AGGREGATE DATA (SAD) TO IDENTIFY WHICH COMBINATIONS OF INTERVENTIONS WORK BEST FOR WHICH INDIVIDUALS.
Smith E1, Hubbard SJ2, Cooper NJ1, Abrams KR1
1University of Leicester, Leicester, UK, 2UNIVERSITY OF LEICESTER, LEICESTER, UK

RESEARCH ON METHODS - Patient-Reported Outcomes Studies
PRM154
F18
CAREGIVER BURDEN IN DAILY HUMAN GROWTH HORMONE INJECTIONS FOR CHILDREN
Loftus J1, Lamoureux RE2, Yaworsky A3, Shields AL4, Morrissey L4, Kelly M4, Love E4, Pleil A5, Hart G6, Hershkovitz O6, Turner-Bowker DM4
1Pfizer Ltd, Tadworth, UK, 2Adelphi Values, USA, Boston, MA, USA, 3Adelphi Values USA, Boston, MA, USA, 4Adelphi Values, Boston, MA, USA, 5Pfizer Inc, San Diego, CA, USA, 6OPKO Biologics, Ness Ziona, Israel

PRM155
F19
PSYCHOMETRIC PROPERTIES OF THE EQ-5D-5L IN PATIENTS WITH MAJOR DEPRESSION DISORDER
Bilbao A1, García-Perez L2, Retolaza-Balsategui A3, Mendezona-Peña JI4, Estebanez S5, Vazquez de la Torre-Escalera P6, Ruiz-Quintanal L7, Martín-Fernández J8
1Research Unit, Basurto University Hospital (Osakidetza) – Health Service Research Network on Chronic Diseases (REDISSEC), Bilbao, Spain, 2Fundación Canaria de Investigación Sanitaria (FUNCANIS) – REDISSEC, Tenerife, Spain, 3Basauri Mental Health Center (Osakidetza) – REDISSEC, Basauri, Spain, 4Derio Mental Health Center (Osakidetza), Derio, Spain, 5Research Unit, Basurto University Hospital (Osakidetza), Bilbao, Spain, 6Fuenlabrada Mental Health Center, Fuenlabrada University Hospital, Madrid, Spain, 7Mental Health Unit, University Hospital of Canary Islands, Tenerife, Spain, 8Villamanta Centre, Navalcarnero Health Centre, Madrid Health Service – REDISSEC, Madrid, Spain

PRM156
F20
CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE PEDSQL CARDIAC MODULE VERSION 3.0
Namazova-Baranova L, Vinyarskaya I, Chernikov V, Vishneva E, Soboleva K
FSAI “National Scientific and Practical Center of Children’s Health” of the Ministry of Health of the Russian Federation, Moscow, Russia, Moscow, Russia

PRM157
F21
PREDICTING EQ-5D INDEX SCORES FROM PROMIS PROFILE 29 IN THE UNITED KINGDOM, FRANCE, AND GERMANY
Klapproth CP1, Leplege A2, Gibbons C3, Coste J4, Valderas JM5, Rose M1, Fischer F1
1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Université Paris Diderot, Paris, France, 3University of Cambridge, Cambridge, UK, 4Paris Decartes, Hotel Dieu Hospital , Assistance Publique-Hôpitaux de Paris, Paris, France, 5University of Exeter, Exeter, UK

PRM158
F22
THE CYSTIC FIBROSIS IMPACT QUESTIONNAIRE (CF-IQ): QUALITATIVE DEVELOPMENT AND COGNITIVE EVALUATION OF A NEW PATIENT-REPORTED OUTCOME INSTRUMENT TO ASSESS THE LIFE IMPACTS OF CYSTIC FIBROSIS
McCarrier KP1, Hassan M2, Martin ML1, Suthoff E2, Hodgkins P2
1Health Research Associates, Inc., Seattle, WA, USA, 2Vertex Pharmaceuticals Incorporated, Boston, MA, USA

PRM159
F23
NON-INTERVENTIONAL REAL-WORLD EUROPEAN STUDY QUANTIFYING THE BURDEN OF CENTRAL NERVOUS SYSTEM (CNS) METASTASES ON HEALTHCARE RESOURCE USE (HRU) IN PATIENTS WITH METASTATIC NON-SMALL-CELL LUNG CANCER (MNSCLC) – RESULTS FROM AN INTERIM ANALYSIS
Crane G1, Khan N2, Pedrós M3, Hipp J4, Gally S5, Smoljanovic V6, Gondos A7, Hammerschmidt S8
1Roche (RWD), Welwyn Garden City, UK, 2QuintilesIMS, Mendham, NJ, USA, 3QuintilesIMS, Barcelona, Spain, 4Roche Pharma AG, Grenzach-Wyhlen, Germany, 5Roche SAS, Boulogne-Billancourt, France, 6F. Hoffmann-La Roche Ltd., Basel, Switzerland, 7QuintilesIMS, Frankfurt, Germany, 8Klinikum Chemnitz gGMBH, Chemnitz, Germany

PRM160
F24
DEVELOPMENT AND CONTENT VALIDITY TESTING OF AN ASSESSMENT OF SYMPTOMS AND EXPERIENCES OF PATIENTS WITH ACUTE PANCREATTIS ASSOCIATED WITH SEVERE HYPERTRIGLYCERIDEMIA
Burbridge C1, Randall JA1, Sanchez RJ2, Dansky H2, Symonds T1, Girman C3, Whitcomb D4, Selk K4, Strayer J4, Kershaw E4
1Clinical Outcomes Solutions, Folkestone, Kent,, UK, 2Regeneron Pharmaceuticals, Tarrytown, NY, USA, 3CERobs Consulting LLC, Chapel Hill, NC, USA, 4University of Pittsburgh, Pittsburgh, PA, USA

PRM161
F25
LINGUISTIC VALIDATION OF KNOWLEDGE, ATTITUDES AND PRACTICE OF ZIKA VIRUS DISEASE QUESTIONNAIRE AMONG THE MALAYSIAN GENERAL PUBLIC USING RASCH MODEL: A CROSS-SECTIONAL STUDY
Ahmad S1, Wong IX1, Ahmad Mazlan NA1, Ismail NE2
1MAHSA University, Bandar Saujana Putra, Malaysia, 2MAHSA University, Bandar Saujana Putra, Jenjarom Kuala Langat, Selangor, Malaysia

PRM162
F26
WITHDRAWN

PRM163
F27
EXPLORATORY ANALYSIS OF THE REASONS FOR CREATING WORLDWIDE TRANSLATIONS OF PATIENT REPORTED OUTCOME INSTRUMENTS
Yohe Moore E1, Brandt B2, Poepsel T2, Simpson H3, McKown S2
1Corporate Translations, Inc., Chicago, IL, USA, 2Corporate Translations, Inc., East Hartford, CT, USA, 3Corporate Translations, Inc., Bloxham, UK

PRM164
G1
ASSESSING METHODOLOGIES FOR HEALTH STATE UTILITIES IN PAEDIATRIC INDICATIONS FOR COST-UTILITY ANALYSES: REVIEW OF NICE TECHNOLOGY APPRAISALS FOR PAEDIATRIC INDICATIONS
Khurana V1, Ko JJ2, Bhattacharyya S1, Partha G1, Khare A1, Medin J3
1Novartis Healthcare Private Limited, Hyderabad, India, 2Novartis Pharmaceuticals, East Hanover, NJ, USA, 3Novartis Pharma AG, Basel, Switzerland

PRM165
G2
VALIDATION OF THE EQ-5D-5L IN PATIENTS WITH HIP OR KNEE OSTEOARTHRITIS
Bilbao A1, Martín-Fernández J2, Arenaza JC3, García I4, Tomás-García N5, Trujillo-Martín E6, García-Perez L7
1Research Unit, Basurto University Hospital (Osakidetza) – Health Service Research Network on Chronic Diseases (REDISSEC), Bilbao, Spain, 2Villamanta Centre, Navalcarnero Health Centre, Madrid Health Service – REDISSEC, Madrid, Spain, 3Traumatology and Orthopedic Surgery Service, Basurto University Hospital (Osakidetza) – REDISSEC, Bilbao, Spain, 4Traumatology and Orthopedic Surgery Service, Galdakao-Usansolo Hospital (Osakidetza), Galdakao, Spain, 5San Martin de Valdeiglesias Health Center, Madrid Health Service, Madrid, Spain, 6Rheumatology Service, University Hospital of the Canary Islands, Tenerife, Spain, 7Fundación Canaria de Investigación Sanitaria (FUNCANIS) – REDISSEC, Tenerife, Spain

PRM166
G3
THE SHORT TERM HEALTH RELATED QUALITY OF LIFE (HRQOL) IMPACT ON PATIENT AT THE INTERNAL MEDICINE CLINIC.
Horiuchi H
Kurashiki Central Hospital, Okayama, Japan

PRM167
G4
ACCURATE REPRESENTATION OF PATIENTS’ OPINIONS FOR DECISION-MAKING: ARE ONLINE HEALTH COMMUNITIES GOOD CANDIDATES?
Raïs S1, Radoszycki L2, Dourgnon P3, Rochaix L1, Chekroun M2
1Hospinnomics, Paris, France, 2Carenity, Paris, France, 3IRDES, Paris, France

PRM168
G5
DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF AN OWNER-COMPLETED MEASURE OF FELINE HEALTH AND QUALITY OF LIFE
Tatlock S1, Williamson N1, Arbuckle R1, Gober M2
1Adelphi Values Ltd, Bollington, Cheshire, UK, 2Zoetis, Cochranville, PA, USA

PRM169
G6
CAN THE BARTHEL INDEX (BI) BE RELIABLY USED WITHIN ECONOMIC EVALUATION? AN EXAMINATION OF THE COMPLEMENTARITY OF THE BI AND THE EUROQOL 5 DIMENSIONS 3 LEVEL (EQ-5D-3L).
Kaambwa B
Flinders University, Adelaide, Australia

PRM170
G7
CLINICAL OUTCOME ASSESSMENTS FOR PATIENTS WITH HEMOPHILIA
Burbridge C1, Su J2, Hartford C3, Jain N4, Erly S5, Symonds T1
1Clinical Outcomes Solutions Ltd., Folkestone, Kent, AZ, USA, 2Bioverativ, Waltham, MA, USA, 3Clinical Outcomes Solutions Ltd, USA, Tucson, AZ, USA, 4Bioverativ, Waltham, AZ, USA, 5formerly at Clinical Outcomes Solutions Ltd, Tucson, AZ, USA

PRM171
G8
QUALITATIVE INTERVIEWS TO INFORM DEVELOPMENT OF A PATIENT REPORTED OUTCOME (PRO) STRATEGY IN RLBP1 RETINITIS PIGMENTOSA (RLBP1 RP)
Tolley C1, Mullins A2, Kilgariff S1, Arbuckle R1, Green J3, Burstedt M4, Holopigian K5, Stasi K6, Sloesen B7
1Adelphi Values Ltd, Bollington, Cheshire, UK, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Memorial University of Newfoundland, St. Johns, NF, Canada, 4University of Umea, Umea, Sweden, 5Novartis Institute of Biomedical Research, East Hanover, NJ, USA, 6Novartis Institute of Biomedical Research, Cambridge, MA, USA, 7Novartis Pharma AG, Basel, Switzerland

PRM172
G9
CAN WE USE DEMQOL-PROXY WITH CONFIDENCE? ROBUST SOLUTIONS TO PRACTICAL PROBLEMS
Smith SC1, Hendriks JA1, Cano S2, Black N1
1London School of Hygiene & Tropical Medicine, London, UK, 2Modus Outcomes, Stotfold, UK

PRM173
G10
RELIABILITY AND VALIDITY OF THE MOBILITY SECTION OF THE PROSTHESIS EVALUATION QUESTIONNAIRE AND ITS MODIFIED VERSION. DO THEY MEASURE THE SAME CONSTRUCT?
Repo JP1, Häkkinen A2, Barner-Rasmussen I1, Kautiainen H3, Roine RP4, Tukiainen EJ1
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Department of Education and Science, Central Finland Health Care District, Jyväskylä, Finland, Jyväskylä, Finland, 3Helsinki and Uusimaa Hospital District, Helsinki, Finland, 4Helsinki University Hospital and University of Eastern Finland, Helsinki, Finland

PRM174
G11
ELECTRONIC PATIENT-REPORTED OUTCOMES: ARE THERE GAPS BETWEEN GUIDANCE AND ISSUES ENCOUNTERED IN PRACTICE?
Williams P1, Itani A2, Brunel V3, Bindi P4, Emery M4, Acquadro C2, Josielewski E5, Anfray C4
1Mapi, Patient-Centered Outcomes, Lyon, France, 2Mapi, Lyon, France, 3Mapi, Language Services, Lyon, France, 4Mapi Research Trust, Lyon, France, 5Mapi, Yardley, PA, USA

PRM175
G12
THE NEED FOR DEVELOPING A DECISION AID TOOL ABOUT FEEDING OPTIONS
López E1, Moreno A2, Rivero C3, Rodríguez A4, Vives I5, Layola Brias M6, Lizan L7
1Complejo Hospitalario Torrecárdenas, Almería, Spain, 2Hospital Universitario da Coruña, A Coruña, Spain, 3Hospital Universitario Virgen Macarena, Sevilla, Spain, 4Hospital Universitario Virgen del Rocío, Sevilla, Spain, 5Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 6Nestle Health Science, Barcelona, Spain, 7Outcomes 10, Universitat Jaume I, Castellon, Spain

PRM176
G13
REDUCING COGNITIVE BURDEN IN DISCRETE CHOICE EXPERIMENTS
Goossens LM1, Jonker MF1, Rutten-van Mölken MP1, Boland MR1, Slok AH2, Salomé PL3, Van Schayck OC2, in 't Veen JC4, Stolk EA5, Donkers B1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Maastricht University, Maastricht, The Netherlands, 3Huisartsencoöperatie PreventZorg, Bilthoven, The Netherlands, 4Franciscus Gasthuis Hospital, Rotterdam, The Netherlands, 5EuroQol Research Foundation, Rotterdam, The Netherlands

PRM177
G14
THE PATIENT-REPORTED APNEA QUESTIONNAIRE (PRAQ): A PROM OPTIMIZED FOR USE ON BOTH INDIVIDUAL PATIENT AND AGGREGATE LEVEL
Abma IL1, Rovers M1, IJff M2, Hol B3, Westert GP1, van der Wees PJ1
1Radboudumc, Nijmegen, The Netherlands, 2ApneuVereniging, Doorn, The Netherlands, 3Albert Schweitzer Ziekenhuis, Zwijndrecht, The Netherlands

PRM178
G15
EVALUATION AND VALIDATION OF THE PROACT MEASURES FOR CANCER PATIENTS AND INFORMAL CAREGIVERS
Shilling VM, Starkings RM, Jenkins VA, Fallowfield LJ
University of Sussex, Falmer, Brighton, UK

PRM179
G16
TOO BROAD TO BE SENSITIVE? EXPLORING THE RESPONSIVENESS OF THE ICECAP-O CAPABILITY WELLBEING MEASURE COMPARED TO THE EQ-5D-3L TO THE CHANGE OF CLINICAL AND QOL ASPECTS IN PEOPLE WITH PARKINSON’S
Xin Y1, Lewsey J1, Gray R2, Clarke CE3, Coast J4, Rick C3, Mcintosh E1
1University of Glasgow, Glasgow, UK, 2University of Oxford, Oxford, UK, 3University of Birmingham, Birmingham, UK, 4University of Bristol, Bristol, UK

PRM180
G17
TERMS REQUIRING MULTIPLE TRANSLATIONS OR A DESCRIPTIVE TRANSLATION IN THE TARGET LANGUAGE AND VICE VERSA
Scharf L, Mead H
ICON Plc, Abingdon, UK

PRM181
G18
ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIASIS COMPARED WITH THE PORTUGUESE POPULATION
Ferreira LN1, Oliveira Martins S2, Moital I3, Ferreira P4, Varela P5, Oliveira H6, Laires PA3, Cabrita J2
1Universidade do Algarve, Faro, Portugal, 2Faculty of Pharmacy UL, Lisbon, Portugal, 3Novartis Farma Portugal, Porto Salvo, Portugal, 4Hospital CUF Descobertas, Lisbon, Portugal, 5Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal, 6Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

PRM182
G19
THE INFLUENCE OF AGE ON PATIENT ATTITUDES AND ACCEPTABILITY TOWARDS USING THEIR OWN MOBILE DEVICE TO RECORD PATIENT-REPORTED OUTCOMES DATA IN CLINICAL TRIALS
Byrom B1, Muehlhausen W2, Flood E3, Cassedy C3, Skerritt B2, McCarthy M2
1ICON Clinical Research, Marlow, UK, 2ICON Clinical Research, Dublin, Ireland, 3ICON Clinical Research, Gaithersburg, MD, USA

PRM183
G20
COMPARING THE METHODS OF INCORPORATING THE HEALTH RELATED QUALITY OF LIFE OF ADVANCED CANCER PATIENTS IN ECONOMIC MODELS
O'Connor J, Hodgson R, Claxton L
University of York, York, UK

PRM184
G21
EVALUATING PATIENT REPORTED OUTCOMES COMMONLY USED IN CURRENT LUNG CANCER CLINICAL TRIALS
Grimes R, Grant L, Kaur S, Spencer H, Brookes B, Bennett B
Adelphi Values Ltd, Bollington, Cheshire, UK

PRM185
G22
FUNCTIONAL ASSESSMENT AFTER TREATMENT OF UPPER EXTREMITY SOFT TISSUE SARCOMAS USING STRUCTURED OUTCOME MEASURES: A SYSTEMATIC REVIEW
Kjäldman M1, Repo JP1, Sampo M2, Barner-Rasmussen I1, Blomqvist C2, Kask G1, Tukiainen EJ1
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Helsinki University Central Hospital, Helsinki, Finland

PRM186
G23
QUALITATIVE RESEARCH METHODS FOR COLLECTING, ANALYZING, AND PRESENTING PATIENT-REPORTED DATA ON NOTICEABLE AND IMPORTANT CHANGE IN DISEASE-RELATED SIGNS AND SYMPTOMS
Mazar I1, Stokes J1, Foley C2, Galipeau N2, Shields AL1
1Adelphi Values, Boston, MA, USA, 2Adelphi Values USA, Boston, MA, USA

PRM187
G24
THE RISKS IN TRANSLATING SMARTPHONE STRINGS FOR MEDICAL STUDY SMARTPHONES APPS & SMARTWATCHES
Richards A, King KM
ICON Plc, Abingdon, UK

PRM188
G25
“IT’S ALL RELATIVE” – EXPLORING THE CHALLENGES DURING CULTURAL ADAPTATION OF FAMILY NAMES IN PRO (PATIENT REPORTED OUTCOMES) QUESTIONNAIRES
Oke L, Neewoor S, Gay F
ICON Plc, Abingdon, UK

PRM189
G26
FINDING THE PATIENT IN CLINICAL MEANINGFULNESS THROUGH RIGOROUS COGNITIVE INTERVIEWS
Lasch K
Pharmerit International, Newton, MA, USA

PRM190
G27
COGNITIVE DEBRIEFING OF THE DMD-SPECIFIC MEASURES OF PHYSICAL FUNCTIONING – CAREGIVER QUESTIONNAIRE
White MK1, Macary C2, Leffler M3, Rychlec K1, Martin D2, Sikora Kessler A1, Jones C4, Kosinski M1
1Optum, Johnston, RI, USA, 2Sarepta Therapeutics, Cambridge, MA, USA, 3Casimir LLC, Bellevue, WA, USA, 4CJ Strategy and Communications, Boston, MA, USA

PRM191
G28
COGNITIVE INTERVIEWING DURING LINGUISTIC VALIDATION OF CLINICAL OUTCOMES ASSESSMENTS (COAS): IN-PERSON OR VIDEO CHAT – AN ANALYSIS OF RESPONDENT PREFERENCE
Sweeney E, May M, Vlad-McCabe M
TransPerfect, New York, NY, USA

PRM192
G29
COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC U100 COMPARED WITH INSULIN GLARGINE U100 IN GREECE
Yfantopoulos J, Chantzaras A
University of Athens, ATHENS, Greece

PRM193
G30
WHAT TIME DO WE DINE?”- A CULTURAL STUDY TO EVALUATE PEOPLE’S VIEWS OF SET MEAL TIMES ACROSS COUNTRIES
Lear A1, Towns L2
1ICON PLC, Abingdon, UK, 2ICON Plc, Abingdon, UK

PRM194
G31
USING RASCH MEASUREMENT TO QUANTIFY THE PERCEIVED RISKS ASSOCIATED WITH THE USE OF TOBACCO AND NICOTINE-CONTAINING PRODUCTS
Chrea C1, Cano S2, Salzberger T3, Alfieri T4, Mainy N1, Ramazzotti A5, Weitkunat R1, Lüdicke F1
1PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland, 2ScaleReport, Stotfold, UK, 3University of Economics and Business, Vienna, Austria, 4Covance Market Access Inc, San Diego, CA, USA, 5Philip Morris International Management S.A., Lausanne, Switzerland

PRM195
G32
THE DEVELOPMENT AND USE OF A PRELIMINARY CONCEPTUAL MODEL OF INFLAMMATORY BOWEL DISEASE (IBD) TO FACILITATE PATIENT REPORTED OUTCOME (PRO) INSTRUMENT SELECTION FOR A UK REAL-WORLD EVIDENCE STUDY
Rylands AJ1, Owen G2, Toms J2, Heggs N2, Bottomley CJ1
1pH Associates (an OPEN Health company), Marlow, UK, 2Takeda UK Ltd., High Wycombe, UK

PRM196
G33
TRANSLATION AND CULTURAL ADAPTATION OF THE BODY-Q CHEST MODULE INTO FINNISH FOR USE IN GYNECOMASTIA, WEIGHT LOSS AND FTM CHEST SURGERY
Repo JP1, Klassen A2, Homsy P1, Lindford A1, Popov P1
1University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2McMaster University, Hamilton, ON, Canada

PRM197
G34
WHEN AND WHERE TO USE FURIGANA? THE APPLICATION OF PHONETIC NOTATION IN JAPANESE TRANSLATIONS OF CLINICAL OUTCOMES ASSESSMENTS (COAS) FOR CHILDREN
Richards A, D'Arezzo K, King KM
ICON Plc, Abingdon, UK

PRM198
G35
VALUE HEALTH WITH A MOBILE APP: THE INFANT HEALTH-RELATED QUALITY OF LIFE INSTRUMENT
Jabrayilov R1, van Asselt T1, Vermeulen KM1, Volger S2, Detzel P3, Dainelli L3, Krabbe PF1
1University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2Nestle Nutrition R&D, King of Prussia, PA, USA, 3Nestle Research Center, Lausanne, Switzerland

PRM199
H1
VALUE OF A PILOT STUDY IN A RETROSPECTIVE CHART REVIEW: FINAL PROTOCOL DESIGN SHOULD BASE ON PILOT RESULTS
Rillmann BK
PRA Health Sciences, Mannheim, Germany

PRM200
H2
STUDY OF POLYPHARMACY AT A TERTIARY CARE TEACHING HOSPITAL BANGALORE
Samnejad B
al-ameen college of pharmacy, bangalore, India

RESEARCH ON METHODS - Statistical Methods
PRM201
H3
RESULTS OF INDIVIDUAL PARTICIPANT DATA META-ANALYSIS VS AGGREGATE DATA META-ANALYSIS OF RCTS OF EXERCISE REHABILITATION IN CHRONIC HEART FAILURE
Walker S, Ciani O, Taylor RS and on behalf of the ExTraMATCH II steering commitee R
University of Exeter, Exeter, UK

PRM202
H4
SECOND-LINE TREATMENTS FOR ADVANCED GASTRIC CANCER: A NETWORK META-ANALYSIS OF OVERALL SURVIVAL USING PARAMETRIC MODELLING METHODS
Harvey RC
Tolley Health Economics Ltd., Buxton, UK

PRM203
H5
ASSESSING THE ROBUSTNESS OF NETWORK META-ANALYSIS OF ATYPICAL ANTIPSYCHOTICS IN THE PRESENCE OF HETEROGENEITY
Ainsworth CM, Vickers AD, Le Moine J
RTI Health Solutions, Manchester, UK

PRM204
H6
ESTIMATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CANCER PATIENTS UTILISING A TIME-TO-DEATH ANALYSIS
Harvey RC, Tolley K, Cranmer HL
Tolley Health Economics Ltd., Buxton, UK

PRM205
H7
CHALLENGES IN DEMONSTRATING DISEASE-MODIFYING EFFECTS: EVIDENCE-BASED TESTING OF A NOVEL STATISTICAL APPROACH IN ALZHEIMER’S DISEASE
Onishchenko K, Jones C, Ruff L
Consulting at McCann Health, London, UK

PRM206
H8
HOW BENEFICIAL IS INDIVIDUAL PATIENT DATA IN A MIXED TREATMENT COMPARISON?
Leahy J1, Gray E2, O'Leary A3, Walsh C4
1Trinity College Dublin, Dublin 2, Ireland, 2School of Medicine, Trinity College Dublin, Dublin, Ireland, 3National Centre of Pharmacoeconomics, Dublin 8, Ireland, 4University of Limerick, Castletroy, Ireland

PRM207
H9
MINIMIZING BIAS IN PARAMETRIC SURVIVAL ANALYSES OF PUBLISHED KAPLAN-MEIER CURVES
Rael M1, Ishak J2
1Evidera, San Francisco, CA, USA, 2Evidera, Montreal, QC, Canada

PRM208
H10
THE USE OF INTRA-CLASS CORRELATION COEFFICIENTS TO ASSESS TEST-RETEST RELIABILITIES IN PSYCHOMETRIC EVALUATIONS OF PATIENT REPORTED OUTCOME MEASURES
Sen R, Yip C, Severson K
Adelphi Values USA, Boston, MA, USA

PRM209
H11
VALUE OF INFORMATION ANALYSIS USING GENERALIZED ADDITIVE MODEL REGRESSION: A CASE STUDY IN HEART FAILURE DISEASE MANAGEMENT
Cao Q1, Buskens E2, Postma MJ1, Postmus D3
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands, 3University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

PRM210
H12
DIFFERENCES IN LABOUR PARTICIPATION BETWEEN PEOPLE LIVING WITH HIV AND THE GENERAL POPULATION: RESULTS FROM SPAIN ALONG THE BUSINESS CYCLE
Peña-Longobardo LM, Oliva-Moreno J
University of Castilla-La Mancha, Toledo, Spain

PRM211
H13
CHANGES IN PRIVATE FINANCING OF THE GREEK HEALTH SYSTEM DURING THE ECONOMIC CRISIS
Yfantopoulos J1, Chantzaras A1, Ollandezos M2
1University of Athens, ATHENS, Greece, 2PANHELLENIC ASSOCIATION OF PHARMACEUTICAL INDUSTRY, ATHENS, Greece

PRM212
H14
IMPACT OF NON-RANDOMISED DROP-OUT ON TREATMENT SWITCHING ADJUSTMENT IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY
Bell Gorrod H1, Latimer N1, Damian D2, Hettle R3, Harty GT4, Wong SL2
1University of Sheffield, Sheffield, UK, 2EMD Serono, Inc., Billerica, MA, USA, 3PAREXEL International, London, UK, 4Merck Serono, London, UK

PRM213
H15
QUALITY OF REPORTING AND ANALYSIS OF TRIAL-BASED COST EFECTIVENESS EVALUATIONS IN OBSTETRICS AND GYNAECOLOGY; A SYSTEMATIC REVIEW
El Alili M1, van Dongen JM1, Huirne J2, van Tulder MW1, Bosmans JE1
1Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands

PRM214
H16
WITHDRAWN

PRM215
H17
MAXIMUM DIFFERENCE SCALING TO ENHANCE INSIGHT IN QUALITATIVE PAYER RESEARCH
Jones-Phillips DL, Bradshaw SE
Valid Insight, London, UK

PRM216
H18
THE USE OF MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) AND SIMULATED TREATMENT COMPARISON (STC) IN HTA SUBMISSIONS; LEARNINGS FROM RECENT SUBMISSIONS
Pooley N, Papageorgakopoulou C, Adkins E, Payne R
PHMR Ltd, London, UK

PRM217
H19
AN ACCESSIBLE COMPARISON OF TRADITIONAL STATISTICAL AND MACHINE LEARNING APPROACHES TO ANALYSIS OF REAL WORLD DATA: WHICH, WHEN AND WHY?
Merinopoulou E1, Oguz M1, Chu BC2, McDonald L3, Ulvestad M4, Cox A1, Ramagopalan S3
1Evidera, London, UK, 2Evidera, Bethesda, MD, USA, 3Bristol-Myers Squibb, Uxbridge, UK, 4Bristol-Myers Squibb, Oslo, Norway

PRM218
H20
MINIMIZING BIAS IN INDIRECT COMPARISONS UTILIZING VIRTUAL PATIENT LEVEL DATA
Rael M1, Ishak J2
1Evidera, San Francisco, CA, USA, 2Evidera, Montreal, QC, Canada

PRM219
H21
REPORTING QUALITY & TRANSPARENCY OF PUBLISHED NETWORK META-ANALYSIS. IS IT SATISFACTORY?
Kopieć A, Nikodem M
Arcana Institute, Krakow, Poland

PRM220
H22
EVIDENCE SYNTHESIS FOR HEALTH TECHNOLOGY ASSESSMENT WITH LIMITED STUDIES
Ren S, Oakley JE, Stevens JW
University of Sheffield, Sheffield, UK

PRM221
H23
GENERIC REIMBURSED MARKET SHARES IN GREECE FROM 2012-2016. A STUDY BASED ON AGE GROUP PREFERENCES.
Dede Z1, Manias NG2
1Pricing Committee, ATHENS, Greece, 2MINTE, Athens, Greece

PRM222
H24
FRACTIONAL POLYNOMIAL NMA MODELS FOR SURVIVAL ANALYSES: RESULTS FROM A SIMULATION STUDY
Laliman VA1, Pacou M2, Gauthier A3
1Amaris, Toronto, ON, Canada, 2Amaris, Paris, France, 3Amaris, London, UK

PRM223
H25
ASSESSING THE ROBUSTNESS OF DIRECT META-ANALYSIS IN THE PRESENCE OF HETEROGENEITY
Ainsworth CM
RTI Health Solutions, Manchester, UK

PRM224
H26
MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC): SENSITIVITY ANALYSES AND GRAPHICAL DIAGNOSTICS
Signorovitch J, Gao W, Rybkin V, Yao Z, Hellstern M
Analysis Group, Inc., Boston, MA, USA

PRM225
H27
APPLICATION OF BALANCING TECHNIQUES IN STUDIES UTILIZING GERMAN ADMINISTRATIVE CLAIMS DATA
Meise D, Kohlscheen KM, Jacob C, Braun S
Xcenda GmbH, Hannover, Germany

PRM226
H28
OVERALL SURVIVAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A COMPARISON OF CLINICAL TRIAL VERSUS REAL-WORLD OUTCOMES USING A PROPENSITY SCORE REWEIGHTING APPROACH
Mueller S1, Heeg B2, van Oostrum I2, Wilke T1
1Ingress-Health HWM GmbH, Wismar, Germany, 2Ingress Health, Rotterdam, The Netherlands

PRM227
WITHDRAWN

PRM228
H29
WHICH PSM METHOD TO USE? ASSOCIATION BETWEEN CHOSEN PPROPENSITY SCORE METHOD AND OUTCOMES OF RETROSPECTIVE REAL-WORLD TREATMENT COMPARISIONS: EVALUATION OF 18 DIFFERENT PSM METHODS
Groth A1, Mueller S2, Wilke T1
1IPAM, Wismar, Germany, 2Ingress-Health HWM GmbH, Wismar, Germany

RESEARCH ON METHODS - Study Design
PRM229
H30
CLASSIFICATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SEVERITY ACCORDING TO THE GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD): VARIATIONS IN THE DEFINTION OF GOLD GROUPS AND THEIR IMPACT ON STAGE ASSIGNMENT
Gottschalk F1, Mueller S1, Groth A1, Driessen M2, Wilke T3
1IPAM, Wismar, Germany, 2GlaxoSmithKline, London, UK, 3Ingress-Health HWM GmbH, Wismar, Germany

PRM230
H31
TRENDS IN PRAGMATIC CLINICAL TRIALS
Kloc K1, Pisarczyk K1, Lach S1, Rémuzat C2, Toumi M3
1Creativ-Ceutical, Krakow, Poland, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France

PRM231
H32
APPLICATION OF MIXED-METHOD STUDY DESIGNS IN HEALTH- ECONOMIC- RELATED STUDIES. A NARRATIVE REVIEW.
Kuchenbecker U, Günther J, Mittendorf T
Xcenda GmbH, Hannover, Germany

PRM232
H33
CONSISTENCY ASSESSMENT OF INTERNATIONAL DRUG PRICE COMPARISONS
Makowski A1, Tilleul P2, Poisson N3, Degrassat-Théas A4
1Paris Descartes University, Paris, France, 2Nantes Hospital University, nantes, France, 3AP-HP, AGEPS, Paris, France, 4General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, Paris, France

PRM233
H34
ADVANCED MONTE-CARLO SAMPLING SCHEMES FOR VALUE OF INFORMATION ESTIMATION
Thom H1, Fang W1, Wang Z1, Welton NJ1, Goda T2, Giles M3
1University of Bristol, Bristol, UK, 2University of Tokyo, Tokyo, Japan, 3University of Oxford, Oxford, UK

PRM234
H35
ASSESSING PREFERENCES IN DISCRETE CHOICE EXPERIMENTS (DCES): EFFECTS OF THE APPLIED DESIGN ON THE STUDY RESULTS
Mueller S, Bauer S, Wilke T
Ingress-Health HWM GmbH, Wismar, Germany

PRM235
I1
WHAT'S THE REALITY OF REAL-WORLD EVIDENCE IN HEALTH TECHNOLOGY APPRAISAL?
Sarri G, Lambrelli D, Gulea C, GomezEspinosa E, Iheanacho I
Evidera, London, UK

PRM236
I2
ELECTRONIC CAPTURE OF CLINICAL OUTCOME ASSESSMENT DATA: WHY IS IT NOT USED MORE IN CLINICAL STUDIES?
Barsdorf AI1, McQuarrie K2, Vallow S3, Crescioni M4, Eremenco S4
1Pfizer, Inc, New York, NY, USA, 2Janssen Research & Development, LLC, Spring House, PA, USA, 3MedAvante, Hamilton, NJ, USA, 4Critical Path Institute, Tucson, AZ, USA

PRM237
I3
EXPECTED VALUE OF INFORMATION ANALYSIS TO EVALUATE THE POTENTIAL GAINS OF AN RCT COMPARING WOUND DRESSINGS
Welton NJ1, Blazeby JM1, Reeves B1, Rogers C1, Dumville J2
1University of Bristol, Bristol, UK, 2University of Manchester, Manchester, UK

PRM238
I4
LISTENING TO THE “PATIENT VOICE” TO IMPROVE DESIGN AND INTERPRETATION OF SECONDARY ANALYSES: AN EXAMPLE IN ATRIAL FIBRILLATION
Oehrlein EM1, Albrecht J2, Perfetto EM1, McCall D3, Cooke CE1, Slejko JF1, dosReis S1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland, School of Medicine, Baltimore, MD, USA, 3Health eHeart Alliance Steering Committee, Murrieta, CA, USA

PRM239
I5
THE IMPACT OF TRIAL DESIGN ON NETWORK META-ANALYSIS AND DECISION-MAKING: A WORKING EXAMPLE IN ULCERATIVE COLITIS
Bowe C1, Upton CM1, Curry A1, Ralston S2
1SIRIUS Market Access, London, UK, 2SIRIUS, London, UK

PRM240
I6
IDENTIFYING ATTRIBUTES OF CANCER TREATMENTS: WHAT DO STAKEHOLDERS CONSIDER IMPORTANT?
Baba C1, Briggs A1, Mcintosh E1, Lipitz-Snyderman A2, Kaltenboeck A2, Bach PB2
1University of Glasgow, Glasgow, UK, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA

PRM241
I7
EVALUATING ROBOTREVIEWER FOR AUTOMATED RISK OF BIAS ASSESSMENT IN A SYSTEMATIC REVIEW: A CASE STUDY
Edwards M1, Marshall C2
1York Health Economics Consortium, York, UK, 2York Health Economics Consortium Ltd, York, UK

PRM242
I8
AN EXPLORATION OF THE METHODOLOGY OF PUBLISHED SYSTEMATIC LITERATURE REVIEWS ON “BURDEN OF DISEASE”
Buchanan-Hughes AM, Beaver S, Fell B, Summers J, Young E
Costello Medical Consulting Ltd, Cambridge, UK

PRM243
I9
3-STEPS STRAGETY FOR PATIENTS EARLY ACCESS TO AN UNAUTHORIZED MEDICATION / DEVICE PROJECT DESIGN (BASED ON 23 PROJECTS ANALYSES INCLUDING EAP, CUP, NPP, IND, ATU)
Kolochavina M1, Niven D2
1INC Research, Berlin, UK, 2INC Research, London, UK

PRM244
I10
EMBEDDING RANDOMIZED CONTROLLED TRIALS INTO MEDICAL PRACTICE
Ouwens MJ
Astrazeneca, Molndal, Sweden

RESEARCH ON METHODS - Conceptual Papers
PRM245
I11
GAMIFICATION, WHAT IS IT AND HOW CAN IT BE USED IN HEALTH OUTCOMES RESEARCH?
Acquadro M, Arnould B
Mapi, Patient-Centered Outcomes, Lyon, France

PRM246
I12
MAPPING THE SYSTEMATIC REVIEW TOOLBOX
Sutton A1, Marshall C2
1University of Sheffield, Sheffield, UK, 2York Health Economics Consortium Ltd, York, UK

PRM247
I13
REAL WORLD DATA IN FRANCE – STATE OF THE ART
Gurnot S1, Tardu J2, Hirtz B2, Soudani S2, Defrance M2
1Paris-Dauphine, Paris, France, 2Paris-dauphine, Paris, France

PRM248
I14
A CONCEPTUAL MODEL OF THE ECONOMICS OF VISUALIZATION IN DIAGNOSTICS AND SURGERY
Schneider JE1, Briggs A2, Stojanovic I1, Wall B3
1Avalon Health Economics, Morristown, NJ, USA, 2University of Glasgow, Glasgow, UK, 3Olympus, Southborough, MA, USA

PRM249
I15
DISEASE BURDEN MAPPING IN RARE DISEASES: AN EXAMPLE OF HYPOPHOSPHATASIA
Parthenaki I, Balvanyos J, Palkmets O
Dolon Ltd, London, UK

PRM250
I16
THE USE OF THE EORTC ITEM LIBRARY TO SUPPLEMENT EORTC QUALITY OF LIFE INSTRUMENTS
Kulis D1, Bottomley A1, Whittaker C1, van de Poll-Franse LV2, Darlington A3, Holzner B4, Koller M5, Reijneveld JC6, Tomaszewski K7, Grønvold M8
1EORTC, Brussels, Belgium, 2Netherland Comprehensive Cancer Organisation, Eindhoven, The Netherlands, 3University of Southampton, Southampton, UK, 4Medical University of Innsbruck, Innsbruck, Austria, 5University Hospital Regensburg, Regensburg, Germany, 6VU University Medical Center, Amsterdam, The Netherlands, 7Ignatianum Academy, Krakow, Poland, 8University of Copenhagen, Copenhagen, Denmark

PRM251
I17
ASSESSMENT OF ECONOMIC MODEL STABILITY BY REPEATED ONE-WAY SENSITIVITY ANALYSIS
Bloudek LM, O'Day K
Xcenda, Palm Harbor, FL, USA

PRM252
I18
EXPECTED VALUE OF SAMPLE INFORMATION FOR INDIVIDUAL LEVEL SIMULATION MODELS TO INFORM STOP/GO DECISION MAKING BY PUBLIC RESEARCH FUNDERS: A METHODOLOGY FOR THE DAFNEPLUS DIABETES EDUCATION CLUSTER RCT
Brennan A, Pollard D, Coates L, Strong M, Heller S
University of Sheffield, Sheffield, UK

PRM253
I19
A ROBUST, REPRODUCIBLE METHOD FOR EVALUATING THE SUITABILITY OF DISPARATE OBSERVATIONAL DATABASES FOR POOLED ANALYSIS, USING THE OMOP COMMON DATA MODEL
Reisinger SJ1, McDonald L2, Carroll R3, O'Hara DJ1, Anstatt D4, Ramagopalan S2
1Evidera, Harrisburg, PA, USA, 2Bristol-Myers Squibb, Uxbridge, UK, 3Evidera, London, UK, 4Bristol-Myers Squibb, Lawrence Township, NJ, USA

PRM254
I20
COMPARISON OF WEIGHTING METHODS USED DURING THE CONSTRUCTION OF MULTIPLE-CRITERIA DECISION ANALYSIS TOOL FOR REPEATED USE IN LOWER INCOME COUNTRIES
Molnar A1, Nemeth B1, Inotai A1, Kaló Z2
1Syreon Research Institute, Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary

PRM255
I21
REVISITING INDIRECT HEALTH PREFERENCE ELICITATION AS A BASE CASE
Disher T, Beaubien L
Dalhousie University, Halifax, NS, Canada

PRM256
I22
ENGAGING PATIENTS IN THE DEVELOPMENT AND VALIDATION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES AS PARTNERS, NOT JUST PARTICIPANTS
Panter C, Wells J, Williamson N, Kaur S, Tatlock S, Hall R, Gater A
Adelphi Values Ltd, Bollington, Cheshire, UK

PRM257
I23
EFFICIENT SECONDARY USE OF REPRESENTATIVE SOCIAL AND HEALTH CARE DATA IN FINLAND: ISAACUS DATA LAKE, ANALYTICS AND KNOWLEDGE MANAGEMENT PRE-PRODUCTION PROJECT
Soini E1, Hallinen T1, Kekoni A2, Kotimaa J2, Nykänen M3, Tirkkonen J3, Tervahauta M2
1ESiOR Oy, Kuopio, Finland, 2City of Kuopio, Kuopio, Finland, 3Istekki Oy, Kuopio, Finland

PRM258
I24
NETWORK META-ANALYSIS IN THE EVALUATION OF VACCINES
McGirr A1, Widenmaier R1, Burnett H2, Curran D3, Espie E3, Mrkvan T3, Oostvogels L3, Simone B3, McElhaney J4
1GSK Canada, Mississauga, ON, Canada, 2Mapi, Dundas, ON, Canada, 3GSK, Wavre, Belgium, 4Health Sciences North Research institute, Sudbury, ON, Canada

PRM259
I25
BEYOND PRODUCT VALUE - A HOLISTIC APPROACH FOR VALUE ASSESSMENT
Miltenburger C1, Borgstrom F2
1Miltenburger Consulting Berlin, Berlin, Germany, 2Quantify Research AB, Stockholm, Sweden

PRM260
I26
CONSIDERATIONS FOR THE SELECTION OF WRITTEN CHINESE VARIANTS IN THE PROCESS OF TRANSLATING AND LINGUISTICALLY VALIDATING CLINICAL OUTCOME ASSESSMENTS (COAS)
Poepsel T1, Brandt B1, Yohe Moore E2, Simpson H3, McKown S1
1Corporate Translations, Inc., East Hartford, CT, USA, 2Corporate Translations, Inc., Chicago, IL, USA, 3Corporate Translations, Inc., Bloxham, UK

PRM261
I27
SPECIAL CONSIDERATIONS FOR CONDUCTING QUALITATIVE INTERVIEWS WITH CANCER PATIENTS AND THEIR CAREGIVERS FOR THE PURPOSE OF DEVELOPING CLINICAL OUTCOME ASSESSMENTS
Spencer H, Grant L, Kaur S, Grimes R, Brookes B, Bennett B
Adelphi Values Ltd, Bollington, Cheshire, UK

PRM262
I28
GROUP CONCEPT MAPPING AS A STRATEGY FOR DEFINING PATIENT-CENTERED OUTCOMES IN PROMS AND PRO-PMS
Chiauzzi E, McCaffrey S
PatientsLikeMe, Cambridge, MA, USA

PRM263
I29
USING A MIXED METHODS APPROACH TO DETERMINE THE ITEM-SCALE STRUCTURE AND SCORING FOR CLINICAL OUTCOME ASSESSMENTS
Williamson N, Johnson C, Cocks K, Bennett B, Tolley C, Simpson S
Adelphi Values Ltd, Bollington, Cheshire, UK

PRM264
I30
CONCEPTUAL MODELING FRAMEWORK FOR GLOBAL FUNCTIONING OF ADHD PATIENTS
Freriks RD1, Cao Q1, van der Schans J1, Dijk HH1, Groenman AP2, Hoekstra PJ2, Postma MJ1, Buskens E2, Mierau JO1
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands

PRM265
I31
DEVELOPING NEW PRACTICE MODEL TO ENSURE BETTER MEDICATION CONCORDANCE
Amir M
Ziauddin Univeristy, Karach, Pakistan

PRM266
I32
MEASURING CHANGES IN PATTERNS OF TOBACCO PRODUCT USE OVER TIME: TRANSITION PROBABILITY APPROACHES
Afolalu EF1, Prieto L1, de La Bourdonnaye G1, Sponsiello-Wang Z1, Weitkunat R2
1PMI R&D, Philip Morris Products S.A, Neuchâtel, Switzerland, 2PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.